SENTENCE,ITEM 1,ITEM 2,ITEM 3,ITEM 4,ITEM 5
Treatment of allergic rhinitis with intranasal corticosteroids in patients with mild asthma: effect on lower airway responsiveness,0,0,0,0,0
"The effect of treatment of allergic rhinitis with intranasal corticosteroids on lower airway responsiveness was assessed in a randomized, double-blind, placebo-controlled, crossover study",1,1,0,0,0
"Twenty-one young patients with perennial allergic rhinitis and asthma, with documented lower airway hyperresponsiveness (PC20 methacholine < 8 mg/ml), were treated with intranasal aqueous beclomethasone dipropionate and placebo, each given for 4 weeks",0,0,0,0,0
Patients recorded rhinitis and asthma symptom scores and monitored peak expiratory flow rates every morning and evening,0,0,0,0,0
Patients recorded global assessment of rhinitis and global asthma symptom scores at the beginning and end of each treatment,0,0,0,0,0
PC20 methacholine was performed at baseline and at the end of each treatment period,0,0,0,0,0
Intranasal beclomethasone dipropionate significantly reduced global rhinitis symptom scores (p = 0.05) after 4 weeks of treatment,0,0,0,0,0
Global asthma scores did not change significantly (p = 0.2),0,0,0,0,0
"Geometric mean PC20 methacholine improved significantly after 4 weeks of intranasal beclomethasone, but not after placebo (p = 0.04)",0,0,0,0,0
"Daily morning and evening rhinitis symptom scores were lower in patients treated with intranasal corticosteroids over the first 4 weeks of treatment, but carryover effect of steroids precluded comparative analysis of the second 4-week block (morning p = 0.06, evening p = 0.03)",0,0,0,0,0
Morning asthma scores tended to decrease (p = 0.07),0,0,0,0,0
"Evening asthma scores were significantly decreased at weeks 2 and 3 (p = 0.001, p = 0.02, respectively)",0,0,0,0,0
No change in peak expiratory flow rate was seen,0,0,0,0,0
This study confirms that treatment of inflammation in the upper airways indirectly improves asthma symptoms and decreases bronchial hyperreactivity,0,0,0,0,0
Ignoring inflammation in the upper airway may lead to suboptimal results in asthma treatment.,0,0,0,0,0
Once-daily budesonide: 400 micrograms once daily is as effective as 200 micrograms twice daily in controlling childhood asthma,0,0,0,0,0
PETITE Research Group,0,0,0,0,0
One hundred and sixty seven children on 0-200 microgram/day of inhaled steroid with asthma symptoms and sub-optimal peak flow values (less than 90% of that predicted for their height) were randomly allocated either 400 microgram once daily (nocte with placebo o.m.) or 200 mircrogram twice daily of budesonide Turbohaler for 8 weeks,1,0,0,1,0
Bronchdilator usage and symptoms were reduced in both groups at 4 and 8 weeks compared with baseline,0,0,0,0,0
There was a significant increase within both groups in morning and evening PEF after 4 and 8 weeks,0,0,0,0,0
"The increase in evening PEF after 8 weeks was greater in the once-daily group than in the twice-daily group but there were no other significant differences between the groups (morning: +24.6 l/min vs 15.2 l/min, p = 0.059; evening: + 19.7 l/min vs +8.31 l/min; p = 0.013)",0,0,0,0,0
Budesonide Turbohaler 400 microgram once daily is therefore as effective as 200 microgram twice daily in achieving asthma control in children.,0,0,0,0,0
Clinical efficacy of low-dose inhaled budesonide once or twice daily in children with mild asthma not previously treated with steroids,0,0,0,0,0
"The aim of the present study was to examine the efficacy of low-dose inhaled budesonide (BUD) administered via Turbuhaler once or twice daily on symptoms, lung function and bronchial hyperreactivity in children with mild asthma",0,0,0,0,0
"One hundred and sixty-three children (mean age 9.9 yrs, 56 females/107 males) with mild asthma (forced expiratory volume in one second (FEV1) 103% of predicted, morning peak expiratory flow (PEF) 87% pred, reversibility in FEV1 3%, fall in FEV1 after exercise 10.4% from pre-exercise value) and not previously treated with inhaled steroids, were included in a double-blind, randomized, parallel-group study",1,1,0,0,0
"After a two-week run-in period, the children received inhaled BUD 100 microg or 200 microg once daily in the morning, 100 microg twice daily or placebo for 12 weeks",0,0,0,0,0
Exercise and methacholine challenges were performed before and at the end of treatment,0,0,0,0,0
"After 12 weeks of therapy, the fall in FEV1 after an exercise test was significantly less in all three BUD groups (43-5.1%) than in the placebo group (8.6%)",0,0,0,0,0
Bronchial hyperreactivity to methacholine with the provocative dose causing a 20% fall in FEV1 decreased significantly in the BUD 100 microg twice-daily group compared with placebo (ratio at the end of treatment 156%),0,0,0,0,0
Changes in baseline lung function (FEV1 and PEF) were less marked than changes in bronchial responsiveness,0,0,0,0,0
"In conclusion, low doses of inhaled budesonide, given once or twice daily, provided protection against exercise-induced bronchoconstriction in children with mild asthma and near normal lung function.",0,0,0,0,0
Adverse effect of inhaled budesonide (800 μgr) on growth and collagen turnover in children with asthma: a double-blind comparison of once-daily versus twice-daily administration,0,1,0,0,0
"Methods: A randomized, double-blind, crossover trial with 2 treatment periods of 4 weeks was conducted, and growth was assessed with a knemometer",1,1,0,0,0
Objective: To compare short-term growth and markers of collagen turnover during treatment with 800 micrograms of inhaled budesonide administered once daily in the morning and 400 micrograms administered twice daily.,0,0,0,0,0
Patients: Twenty-four children with asthma aged 5.6 to 12.5 years.,0,0,0,0,0
Setting: An outpatient secondary referral center,0,0,0,0,0
Background: Twice-daily administration of inhaled budesonide (400 micrograms) suppresses short-term growth in children with asthma.,0,0,0,0,0
"The carboxy terminal propeptide of type I procollagen, the amino terminal propeptide of type I procollagen (PINP), the carboxy terminal pyridinoline cross-linked telopeptide of type I collagen, the amino terminal propeptide of type III procollagen (PIIINP), and urinary pyridinoline and deoxypyridinoline were evaluated.",0,0,0,0,0
"Results: Mean lower leg growth rate (P = .04), PINP (P = .03), and PIIINP (P < .01) were suppressed during twice-daily administration of budesonide, 400 micrograms",0,0,0,0,0
"Otherwise, no statistically significant differences were detected.",0,0,0,0,0
"Conclusions: As compared with 400 micrograms of inhaled budesonide administered twice daily, 800 micrograms administered once daily in the morning has a sparing effect on short-term growth and collagen turnover.",0,0,0,0,0
Efficacy of once-daily versus twice-daily administration of budesonide by turbuhaler in children with stable asthma,0,0,0,0,0
"We evaluated the efficacy of once-daily versus twice-daily treatment with budesonide, delivered by a Turbuhaler(R), in the management of children with stable asthma in a randomized, double-blind, parallel-group study involving 206 children (age 5-15 years)",1,1,0,0,0
"After a 2-week run-in period during which the children were maintained on their usual dose of budesonide (200 microg or 400 microg/day), patients were randomized to receive the same daily dose in either two daily administrations (morning and evening) or as a single dose in the morning over a period of 12 weeks",1,0,0,1,0
The primary efficacy variable was morning peak expiratory flow (PEF),0,0,0,0,0
The mean morning PEF during the run-in phase was 271 L/min in patients randomized to once-daily treatment and 264 L/min in those randomized to twice-daily treatment,1,0,0,0,0
The mean change from baseline to the last 2 weeks of the treatment period in the two groups was -0.3 L/min (95% confidence limits -6.6 to +6.0) and 2.5 L/min (-4.3 to +9.3),0,0,0,0,0
"The estimated difference between the groups was -2.8 L/min, with 90% confidence limits of -10.4 + 4.5; these were close to the limits regarded as indicative of equivalence (-10 to +10), and hence the difference was not regarded as clinically relevant",0,0,0,0,0
"Similarly, there were no significant differences between the groups in regard to secondary efficacy measures such as spirometric tests and symptom scores",0,0,0,0,0
Both treatments were well tolerated,0,0,0,0,0
We conclude that once-daily administration of budesonide by Turbuhaler(R) is as effective as twice-daily treatment in the management of stable asthma in children treated with inhaled steroids at doses of 200-400 microg/day.,0,0,0,0,0
"A multiple–dosing, placebo–controlled study of budesonide inhalation suspension given once or twice daily for treatment of persistent asthma in young children and infants",0,0,0,0,0
"Rationale: Topical antiinflammatory medications such as inhaled corticosteroids are recommended for therapy of asthma, but no formulation suitable for administration to infants and young children is available in the United States.",0,0,0,0,0
"Methods: This was a 12-week, multicenter, double-blind, randomized, parallel-group study comparing the efficacy and safety of four dosing regimens of bude-sonide inhalation suspension (BIS) or placebo in 480 asthmatic infants and children (64% boys), ages 6 months to 8 years, with moderate persistent asthma",1,1,0,0,0
Approximately 30% of children were previously on inhaled corticosteroids that were discontinued before the study,0,0,0,0,0
"Active treatments were comprised of BIS 0.25 mg once daily (QD), 0.25 mg twice a day (BID), 0.5 mg BID, or 1.0 mg QD",0,0,0,0,0
"Efficacy was assessed by twice daily recording at home of asthma symptom scores and use of rescue medication, and discontinuation from the study because of worsening asthma and/or a requirement for systemic steroids",0,0,0,0,0
Peak flow measurements were recorded twice daily on diary and spirometry was recorded at clinic visits for those children able to perform these tests,0,0,0,0,0
Safety was assessed by reported adverse events and by cortisol testing (adrenocorticotropic hormone stimulation) in a subset of patients,0,0,0,0,0
Results: Patients enrolled had an average duration of asthma of 34 months; the mean asthma symptom score was approximately 1.3 (scale of 0-3),0,0,0,0,0
All dosing regimens with BIS produced statistically significant improvement in various clinical efficacy measures for asthma control compared with placebo,0,0,0,0,0
"The lowest dose used, 0.25 mg QD, was efficacious but with fewer efficacy parameters than seen with the other doses administered",0,0,0,0,0
Separation between active treatment and placebo in daytime and nighttime symptom scores were observed by week 2 of treatment for all BIS treatment regimens,0,0,0,0,0
A significant increase in peak flow measurement was observed in most active treatment groups compared with placebo in the subset of children able to do pulmonary function testing,0,0,0,0,0
All treatment groups showed numerical improvement in forced expiratory volume in 1 second but only the 0.5-mg BID dose was significantly different from placebo,0,0,0,0,0
Adverse events for the entire group and response to adrenocorticotropic hormone in a subgroup of children who underwent cortisol testing before and at the end of the treatment period were no different in budesonide-treated patients in comparison to placebo.,0,0,0,0,0
"Conclusion: Results of this study demonstrate that BIS is effective and safe for infants and young children with moderate persistent asthma in a multiple dose range, and that QD dosing is an important option to be considered by the prescribing physician.",0,0,0,0,0
Low-dose inhaled budesonide once or twice daily for 27 months in children with mild asthma,0,0,0,0,0
This study is an extended follow-up for 24 months of a 12-week trial to study the long-term clinical efficacy of low-dose inhaled budesonide (BUD) once or twice daily in children with mild asthma,0,0,0,0,0
"A total of 122 children (mean age 9.7 years, girls/boys; 42/80) with mild asthma (FEV1 103.7% of predicted, reversibility in FEV1 3.5%, and fall in FEV1 after exercise 12.2%), not previously treated with inhaled steroids, were included in a double-blind, randomized, parallel-group study",1,1,0,0,0
"The children were treated with inhaled BUD 100 or 200 microg administered via Turbuhaler once daily in the morning, 100 microg twice daily, or placebo for 27 months",0,0,0,0,0
"Exercise and methacholine challenges were performed at 3-month intervals the first year and at 6-month intervals the second year, in a total of seven visits",0,0,0,0,0
"A significant dose-response effect favoring BUD 200 microg daily (vs 100 microg daily) was found when comparing changes in FEV1, FEF25%, and FEV50%; the fall in FEV1 after an exercise test; and the effect on blood eosinophils",0,0,0,0,0
Bronchial hyperreactivity to methacholine decreased significantly on three visits in patients treated with BUD 200 microg daily compared to placebo,0,0,0,0,0
Growth rate was not significantly affected except in children aged 7-11 years at baseline after 12 months of treatment,0,0,0,0,0
"In conclusion, 100 or 200 microg daily of inhaled BUD for 27 months is safe and effective in protecting against exercise-induced asthma and achieving nearly normal lung function",0,0,0,0,0
Baseline lung function was not significantly affected in this group of children with mild asthma.,0,0,0,0,0
Efficacy and safety of dry powder fluticasone propionate in children with persistent asthma,0,0,0,0,0
"Background: Flovent Diskus is a powder formulation of the inhaled corticosteroid fluticasone propionate (FP) delivered via a breath-actuated, multidose inhaler.",0,0,0,0,0
Objective: To determine the efficacy and safety of dry powder FP administered once or twice daily (200 microg per day) to children with persistent asthma,0,0,0,0,0
"Methods: Twelve-week, randomized, double-blind, placebo-controlled, multicenter trial with a 52-week, open-label extension",1,1,0,0,0
Children aged 4 to 11 were required to have pulmonary function 50% to 85% of predicted values,0,0,0,0,0
The population was stratified for baseline therapy (inhaled corticosteroid/cromolyn or bronchodilators only),0,0,0,0,0
"After a 2-week placebo run-in, 242 patients received dry powder FP 200 microg each morning, dry powder FP 100 microg BID, or placebo for 12 weeks; 192 were rerandomized to the QD or BID regimen for an additional 52 weeks of open-label treatment",1,0,0,1,0
Primary endpoints were mean changes in FEV1 and morning PEF recorded at clinic visits.,0,0,0,0,0
"Results: Both dry powder FP regimens significantly improved FEV1, evening PEF, and asthma symptoms at the double-blind phase endpoint (P < or = .017 compared with placebo)",0,1,0,0,0
The BID regimen also significantly improved morning PEF and nighttime awakenings due to asthma (P < or = .005),0,0,0,0,0
"Among patients previously treated with inhaled corticosteroids/cromolyn, improvements observed with the QD and BID regimens were similar",0,0,0,0,0
Patients switched from BID to open-label QD treatment showed additional improvements at week 52 generally comparable to patients who received the BID regimen during both phases,0,0,0,0,0
Fluticasone propionate was well tolerated for up to 64 weeks with few reports of drug-related adverse events or morning plasma cortisol abnormalities,0,0,0,0,0
Inhaled fluticasone propionate by Diskus in the treatment of asthma,0,0,0,0,0
Conclusions: Once daily dosing of dry powder FP 200 microg is an effective and convenient alternative for children whose asthma is controlled with a more frequent dosing regimen of inhaled corticosteroids.,0,0,0,0,0
A comparison of the efficacy of the same nomimal dose given either once or twice a da,0,0,0,0,0
"Study objective: In September 2000, the US Food and Drug Administration (FDA) approved the use of Flovent Diskus (FD) [fluticasone propionate; GlaxoSmithKline; Research Triangle Park, NC], which is an orally inhaled, dry-powder corticosteroid, for the maintenance treatment of asthma at dosages of 50 to 1,000 microg administered twice-daily",0,0,0,0,0
Once-daily dosage regimens did not receive approval,0,0,0,0,0
"This article will detail six clinical trials, five of which incorporated comparative once-daily and twice-daily treatment arms of the same nominal dose of FD",0,0,0,0,0
"Results: Twice-daily dosing was numerically superior to once-daily dosing at the same nominal dose in all comparative studies for the primary end point, change in predose FEV(1)",0,0,0,0,0
"Design: Six 12-week, randomized, double-blind, placebo-controlled studies in patients with mild-to-moderate asthma, including two pediatric asthma trials (patient age, 4 to 11 years) of total daily doses of fluticasone propionate (FP) of 100 or 200 microg, and four adult and adolescent studies of total daily doses of FP of 100, 200, or 500 microg",1,1,0,0,0
"In five trials, the results of the once-daily dosage of FP were statistically indistinguishable from those with placebo",0,0,0,0,0
"One trial demonstrated the superiority of FP, 500 microg once-daily, over placebo; however, the effect size was half that observed with twice-daily dosing",0,0,0,0,0
Once-daily FP dosing showed no advantage in safety or in patient adherence to medication,0,0,0,0,0
"Conclusions: In the FDA review of once-daily dosing of the FD regimen, 100 or 200 microg once-daily dosing was not shown to be significantly better than placebo",0,0,0,0,0
"FP 500 microg once-daily was found to be superior to placebo, but at about one half the effect size as the same nominal dose given bid",0,0,0,0,0
"No advantage in patient safety or adherence was demonstrated for once-daily administration over twice-daily administration, and once-daily administration is not currently recommended.",0,0,0,0,0
Is evidence for homeopathy reproducible ?,0,0,0,0,0
"We tested, under independent conditions, the reproducibility of evidence from two previous trials that homoeopathy differs from placebo",0,0,0,0,0
The test model was again homoeopathic immunotherapy,0,0,0,0,0
"28 patients with allergic asthma, most of them sensitive to house-dust mite, were randomly allocated to receive either oral homoeopathic immunotherapy to their principal allergen or identical placebo",1,0,0,0,0
The test treatments were given as a complement to their unaltered conventional care,0,0,0,0,0
A daily visual analogue scale of overall symptom intensity was the outcome measure,0,0,0,0,0
A difference in visual analogue score in favour of homoeopathic immunotherapy appeared within one week of starting treatment and persisted for up to 8 weeks (p = 0.003),0,0,0,0,0
There were similar trends in respiratory function and bronchial reactivity tests,0,0,0,0,0
A meta-analysis of all three trials strengthened the evidence that homoeopathy does more than placebo (p = 0.0004),0,0,0,0,0
Is the reproducibility of evidence in favour of homoeopathy proof of its activity or proof of the clinical trial's capacity to produce false-positive results?,0,0,0,0,0
Use of ultramolecular potencies of allergen to treat asthmatic people allergic to house dust mite: double blind randomised controlled clinical trial,1,1,0,0,0
"Clinic based assessments: forced expiratory volume in one second (FEV1), quality of life, and mood",0,0,0,0,0
"After a four week baseline assessment, participants were randomised to receive oral homoeopathic immunotherapy or placebo and then assessed over 16 weeks with three clinic visits and diary assessments every other week",1,0,0,0,0
38 general practices in Hampshire and Dorset,0,0,0,0,0
"242 people with asthma and positive results to skin prick test for house dust mite; 202 completed clinic based assessments, and 186 completed diary based assessments",0,0,0,0,0
Double blind randomised controlled trial,1,1,0,0,0
To evaluate the efficacy of homoeopathic immunotherapy on lung function and respiratory symptoms in asthmatic people allergic to house dust mite,0,0,0,0,0
"Diary based assessments: morning and evening peak expiratory flow, visual analogue scale of severity of asthma, quality of life, and daily mood",0,0,0,0,0
There was no difference in most outcomes between placebo and homoeopathic immunotherapy,0,0,0,0,0
"There was a different pattern of change over the trial for three of the diary assessments: morning peak expiratory flow (P=0.025), visual analogue scale (P=0.017), and mood (P=0.035)",0,0,0,0,0
At week three there was significant deterioration for visual analogue scale (P=0.047) and mood (P=0.013) in the homoeopathic immunotherapy group compared with the placebo group,0,0,0,0,0
Any improvement in participants' asthma was independent of belief in complementary medicine,0,0,0,0,0
Homoeopathic immunotherapy is not effective in the treatment of patients with asthma,0,0,0,0,0
The different patterns of change between homoeopathic immunotherapy and placebo over the course of the study are unexplained,0,0,0,0,0
Homoeopathic remedies probably have an effect that is greater than placebo,0,0,0,0,0
Some of the better quality homoeopathic studies involve homoeopathic doses of allergens used to treat allergic diseaseIn this study homoeopathic remedies were no better than placebo in the treatment of asthmatic patients who are allergic to house dust mite,0,0,0,0,0
Individualised homeopathy as an adjunct in the treatment of childhood asthma: a randomised placebo controlled trial,1,0,0,0,0
Background: Homeopathy is frequently used to treat asthma in children,0,0,0,0,0
"In the common classical form of homeopathy, prescriptions are individualised for each patient",0,0,0,0,0
There has been no rigorous investigation into this form of treatment for asthma.,0,0,0,0,0
"Methods: In a randomised, double blind, placebo controlled trial the effects of individualised homeopathic remedies were compared with placebo medication in 96 children with mild to moderate asthma as an adjunct to conventional treatment",1,1,0,0,0
The main outcome measure was the active quality of living subscale of the Childhood Asthma Questionnaire administered at baseline and follow up at 12 months,0,0,0,0,0
"Other outcome measures included other subscales of the same questionnaire, peak flow rates, use of medication, symptom scores, days off school, asthma events, global assessment of change, and adverse reactions",0,0,0,0,0
"Other subscales, notably those measuring severity, indicated relative improvements but the sizes of the effects were small",0,0,0,0,0
Results: There were no clinically relevant or statistically significant changes in the active quality of life score,0,0,0,0,0
There were no differences between the groups for other measures.,0,0,0,0,0
"Conclusions: This study provides no evidence that adjunctive homeopathic remedies, as prescribed by experienced homeopathic practitioners, are superior to placebo in improving the quality of life of children with mild to moderate asthma in addition to conventional treatment in primary care.",0,0,0,0,0
negative sample test for item 1,0,0,0,0,0
"this is not a real article, just something to triger negative exemple of the item 1 for test use, to be remove later like any ""pmid"" below 0",0,0,0,0,0
Comparison of 2 iron doses in infants receiving recombinant human erythropoietin therapy,0,0,0,0,0
"Objective: To compare iron sufficiency in premature infants receiving high-dose recombinant human erythropoietin (r-HuEPO), 1200 IU/kg per week, supplemented with 6 or 12 mg/kg per day of enteral iron.",0,0,0,0,0
"Design: We conducted a prospective, double-blind, controlled study of premature infants receiving r-HuEPO therapy, randomly assigned to receive 2 different doses of iron",1,1,0,0,0
"Measurements of ferritin, iron, total iron-binding capacity, reticulocyte count, hemoglobin level, and hematocrit were obtained at baseline, 4, and 6 weeks",0,0,0,0,0
Transferrin saturation was calculated; the number of blood transfusions and the incidences of sepsis were recorded.,0,0,0,0,0
"Setting: This study was performed in the neonatal intensive care unit at Loma Linda University Children's Hospital, Loma Linda, Calif.",0,0,0,0,0
"Subjects: Infants with a gestational age of 32 weeks or younger, older than 7 days, and receiving r-HuEPO therapy from March 1, 1997, to June 30, 1998, were eligible for the study",0,0,0,0,0
Infants were randomly assigned to receive 6 mg/kg per day or 12 mg/kg per day of enteral iron during a course of r-HuEPO therapy for 4 to 6 weeks.,1,0,0,1,0
Results: Sixty-four infants were enrolled in the study,0,0,0,0,0
Twelve infants did not complete the study; 52 completed 4 weeks and 41 completed 6 weeks of the study,0,0,1,0,0
"While ferritin levels and transferrin saturation decreased in both groups over the study period, there were no differences between the 2 study groups.",0,0,0,0,0
Conclusions: Infants receiving high-dose r-HuEPO therapy (1200 IU/kg per week) decrease their ferritin levels (measure of iron stores) even when receiving high enteral iron supplementation,0,0,0,0,0
"Given that the ferritin levels were similar between the 2 groups, we speculate that the additional iron either was not absorbed or was not stored.",0,0,0,0,0
"Comparison between single-dose oral prednisolone and oral dexamethasone in the treatment of croup: a randomized, double-blinded clinical trial",1,1,0,0,0
Objective: To compare the effectiveness of three corticosteroid regimens in children with mild to moderate croup.,0,0,0,0,0
"Methods: Double-blinded, randomized comparative trial with parallel design, conducted in the ED of a paediatric tertiary care hospital",1,1,0,0,0
Children aged 6 months to 6 years presenting to the ED with croup were eligible for inclusion if their Westley croup score was 2 or more,0,0,0,0,0
"They were randomized to receive a single oral dose of either prednisolone 1 mg/kg, dexamethasone 0.15 mg/kg or dexamethasone 0.6 mg/kg",1,0,0,0,0
"Primary outcome measures were the magnitude and rate of reduction in Westley croup score, rate of return for medical care with ongoing croup, and further treatment with steroids in the week following index presentation",0,0,0,0,0
"Secondary outcome measures were the proportion of subjects requiring admission or salvage therapy, such as nebulized adrenaline, during index presentation.",0,0,0,0,0
"Results: A total of 99 children, aged 6-79 months, were enrolled (mean age: 1.7 years)",0,0,0,0,0
"Thirty-four patients were randomized to receive prednisolone 1 mg/kg, 34 to receive dexamethasone 0.15 mg/kg, and 31 to receive dexamethasone 0.6 mg/kg",1,0,0,1,0
Baseline characteristics of the three groups were similar,0,0,0,0,0
The parents of 86 patients (87%) were available for follow-up telephone interview at 1 week,0,0,0,0,0
There were no significant differences in primary or secondary outcome measures between the three treatment groups.,0,0,0,0,0
Conclusions: Both prednisolone 1 mg/kg and low-dose dexamethasone (0.15 mg/kg) were found not to differ in efficacy from the currently recommended 0.6 mg/kg dexamethasone,0,0,0,0,0
The use of these corticosteroid regimens in treating patients with mild to moderate croup is thus supported.,0,0,0,0,0
A randomized comparison of dexamethasone 0.15 mg/kg versus 0.6 mg/kg for the treatment of moderate to severe croup,1,0,0,0,0
"Background: Although previous studies have shown that dexamethasone is useful in croup, the optimal dosage has not been clarified yet",0,0,0,0,0
The aim of this study was to investigate the effectiveness of dexamethasone 0.15 mg/kg single dose compared with the recommended dose of 0.6 mg/kg for treatment of hospitalized children with moderate to severe croup.,0,0,0,0,0
Method: Forty-one children aged 6 months to 5 years admitted from March 2001 to October 2003 at the pediatric ward of Hatyai Hospital with moderate to severe croup were recruited for the study,0,0,0,0,0
"After random allocation, each child received a single intravenous injection of either dexamethasone 0.6 mg/kg (maximum dose 12 mg) or 0.15 mg/kg (maximum dose 3 mg)",1,0,0,0,0
All children were given a single dose of epinephrine nebulization at the beginning of the study,0,0,0,0,0
"The croup scores were measured at 0, 1, 2, 3, 4, 6, 8, 10 and 12 h after the dexamethasone injection.",0,0,0,0,0
"Results: One hour following the injection, the mean croup scores were significantly reduced from baseline values in both groups (p<0.01)",0,0,0,0,0
There was no difference in the mean croup scores between the two groups at any time,0,0,0,0,0
"Median times to croup scores equal or less than two in both high- and low-dose groups were 8 and 7.9 h, respectively",0,0,0,0,0
No patient required intubation or was removed from the study because of a rising croup score after enrollment,0,0,1,0,0
There was no significant adverse reaction from dexamethasone treatment in either group.,0,0,0,0,0
Iron supplementation enhances response to high doses of recombinant human erythropoietin in preterm infants,0,0,0,0,0
Conclusion: Dexamethasone 0.15 and 0.6 mg/kg are equally effective in the treatment of moderate to severe croup.,0,0,0,0,0
To determine whether iron supplementation would enhance erythropoiesis in preterm infants treated with high doses of human recombinant erythropoietin (r-HuEPO).,0,0,0,0,0
"Sixty three preterm infants were randomly allocated at birth to one of three groups to receive: r-HuEPO alone, 1200 IU/kg/week (EPO); or r-HuEPO and iron, 1200 IU/kg/week of r-HuEPO plus 20mg/kg/week of intravenous iron (EPO+iron); or to serve as controls",1,0,0,1,0
All three groups received blood transfusions according to uniform guidelines.,0,0,0,0,0
RESULTS—Infants in the EPO+iron group needed fewer transfusions than controls—mean (95% CI) 1.0 (0.28-1.18) vs 2.9 (1.84-3.88) and received lower volumes of blood—mean (95% CI) 16.7 (4.9-28.6) vs 44.4 (29.0-59.7) ml/kg,0,0,0,0,0
"The EPO group also needed lower volumes of blood than the controls—mean (95% CI) 20.1 (6.2-34.2) vs 44.4(29.0-59.7) ml/kg, but the same number of transfusions, 1.3 (0.54-2.06) vs 2.9 (1.84-3.88)",0,0,0,0,0
"Reticulocyte and haematocrit values from postnatal weeks 5 to 8 were higher in the EPO+iron than in the EPO group, and both groups had higher values than the controls",0,0,0,0,0
"Mean (SEM) plasma ferritin was lower in the EPO group—65 (55) µg/l than in the EPO+iron group 780 (182) µg/l, and 561 (228) µg/l in the control infants.",0,0,0,0,0
CONCLUSIONS—Early administration of high doses of r-HuEPO with iron supplements significantly reduced the need for blood transfusion,0,0,0,0,0
Intravenous iron (20 mg/kg/week in conjunction with r-HuEPO yielded a higher reticulocyte count and haematocrit concentration after the forth week of life than r-HuEPO alone,0,0,0,0,0
Infants treated with r-HuEPO alone showed signs of reduced iron stores.,0,0,0,0,0
Oral iron supplementation in preterm infants treated with erythropoietin,0,0,0,0,0
Background: It is not known whether a moderate dose of oral iron supplementation would further enhance erythropoiesis in recombinant human erythropoietin (EPO)-treated very low-birthweight (VLBW) infants.,0,0,0,0,0
"Methods: In total, 24 preterm infants with birthweights 750-1499 g were enrolled at the age of 14-28 days to receive 400 IU/kg per week EPO subcutaneously for 8 weeks",0,0,0,0,0
The infants were randomly allocated either to receive oral iron supplementation 4 mg/kg per day or to serve as controls.,1,0,0,1,0
"Results: Hemoglobin and the absolute reticulocyte count in the iron supplementation and the control groups remained identical throughout the study period, whereas serum ferritin was significantly lower in the control group at study exit and follow up",0,0,0,0,0
Rates of treatment success (no need for transfusion and hemoglobin never below 8 g/dL) also did not differ between the groups.,0,0,0,0,0
Conclusions: In this study we did not find a clear advantage in a moderate dose of oral iron supplementation on erythropoiesis in EPO-treated VLBW infants,0,0,0,0,0
Whether a higher dose would lead to enhanced erythropoiesis remains to be answered.,0,0,0,0,0
Oral iron is sufficient for erythropoietin treatment of very low birth-weight infant,0,0,0,0,0
The aim of this study was to compare two different doses and means of administration of iron in recombinant human erythropoietin (rHuEPO)-treated very low birth-weight (VLBW) infants,0,0,0,0,0
VLBW infants (n = 41) were randomized to one of three groups,1,0,0,0,0
"Fourteen infants were treated with rHuEPO (300 IU/kg three times a week s.c.) and oral iron (ferrofumarate, 6 mg of iron/kg per day)",0,0,0,0,0
"Another 14 infants received the same erythropoietin dose and intramuscular iron (ferroxypolymaltose, once 12 mg of iron/kg weekly)",0,0,0,0,0
Thirteen infants were treated with the same dose of intramuscular iron but did not receive rHuEPO,0,0,0,0,0
"After the 3-week study period, haemoglobin concentrations and reticulocyte counts were similar in the rHuEPO-treated groups and both were higher than in the group not receiving rHuEPO (P < 0.001)",0,0,0,0,0
In both rHuEPO-treated groups the transferrin receptor concentration increased from 6.8-7.2 mg/l to 10.5-11.3 mg/l.,0,0,0,0,0
Conclusion: In erythropoietin-treated very low birth weight infants the iron need for erythropoiesis can be met by oral administration of iron.,0,0,0,0,0
A comparison of oral and intravenous iron supplementation in preterm infants receiving recombinant erythropoietin,0,0,0,0,0
Objective: To determine whether intravenously administered iron supplements would improve the hematologic response to recombinant erythropoietin in stable preterm infants.,0,0,0,0,0
"Methods: Forty-two preterm infants (<33 weeks' gestation, birth weight < 1500 gm, hematocrit <38%) were treated with recombinant human erythropoietin (Eprex), 600 U/kg per week, and randomly assigned to receive either an oral preparation of ferrous lactate (elemental iron, 12 mg/kg per day) or an intravenous preparation of iron sucrose (6 mg/kg per week).",1,0,0,1,0
"Results: Hematocrits, reticulocyte counts, and transfusions were similar in the oral group (OG) and the intravenous group (IVG)",0,0,0,0,0
"However, markedly higher serum ferritin concentrations were noted in the IVG (p <0.001), and by completion of the study the arithmetic mean values were 265 +/- 127 microg/L versus 137 +/- 65 microg/L in the IVG and the OG, respectively",0,0,0,0,0
The numbers of hypochromic erythrocytes increased in both groups during the study but were significantly higher in the OG (p = 0.04),0,0,0,0,0
Mean daily weight gain in the IVG (27 +/- 6.4 gm/day) was greater than in the OG (22.9 +/- 4.78 gm/day; p = 0.04).,0,0,0,0,0
Conclusions: High doses of both orally administered iron and intravenously administered iron sucrose appear to supply sufficient iron for erythropoiesis in stable infants,0,0,0,0,0
Storage iron may become depleted after oral supplementation,0,0,0,0,0
"The intravenous preparation appears to be safe and maintains serum ferritin concentrations, and it may be indicated for patients with low ferritin levels and for those not established on enteral feedings.",0,0,0,0,0
The Role if High-Dose Oral Iron Supplementation During Erythropoietin Therapy for Anemia of Prematurity,0,0,0,0,0
Objective: To assess whether a high intake of oral iron would increase the effect of recombinant human erythropoietin (rHuEPO) on hemoglobin synthesis.,0,0,0,0,0
"Methods: We studied 30 preterm infants (gestational age 29+/-1.8 weeks, birth weight 1161+/-200 g, at age of 28+/-10 days) who were randomly assigned to receive either 8 mg/kg per day (n=15) or 16 mg/kg per day of oral iron during a course of rHuEPO therapy (900 microg/kg per week) for a duration of 4 weeks",1,0,0,1,0
Both groups were comparable in regard to clinical and laboratory data at the time of enrollment.,0,0,0,0,0
"Results: rHuEPO caused a significant increase in reticulocyte count in the low- and high-dose iron groups, 17.1+/-5.3 to 34.7+/-9.2 and 16.3+/-3.3 to 42.5+/-5.6 (10(9)/l), respectively (p<0.05)",0,0,0,0,0
"However, in both groups, hematocrit values remained stable at the end of the study as compared to baseline (0.35+/-0.03% vs",0,0,0,0,0
"0.30+/-0.03%, 0.35+/-0.05% vs",0,0,0,0,0
"0.30+/-0.03%, NS) and in both groups there was a comparable and significant decrease in ferritin level (259+/-109 to 101+/-40 and 168+/-54 to 69+/-38 microg/l, respectively; p<0.01)",0,0,0,0,0
"The rates of bloody stools without any evidence of necrotizing enterocolitis were not significantly different between the two treatment groups (1/15 vs 4/15, NS).",0,0,0,0,0
Conclusion: We conclude that a higher dose (16 mg/kg per day) of oral iron is not more beneficial when compared to a lower dose (8 mg/kg per day) during rHuEPO therapy for anemia of prematurity,0,0,0,0,0
Further studies will define the optimal dosage and route of administration of iron supplementation during rHuEPO therapy,0,0,0,0,0
Safety and efficacy of ibuprofen versus indomethacin in preterm infants treated for patent ductus arteriosus: a randomised controlled trial,1,0,0,0,0
"Indomethacin (INDO) and, more recently, ibuprofen (IBU) have been used to treat haemodynamically significant patent ductus arteriosus (PDA) in preterm infants",0,0,0,0,0
"Both are cyclo-oxygenase blockers, but seem to have a different influence on regional circulation",0,0,0,0,0
"In a prospective, randomised, controlled study, we compared INDO and IBU with regard to efficacy and safety for the early non-invasive treatment of PDA",1,0,0,0,0
"Doppler echocardiography was used to study 232 preterm infants (gestational age 23-34 weeks) with respiratory distress syndrome of whom 175 had persistent, haemodynamically significant PDA at 48-72 h of life",0,0,0,0,0
"They were randomised to receive three intravenous doses of either INDO (0.2 mg/kg, at 12 h intervals) or IBU (a first 10 mg/kg dose followed by two doses of 5 mg/kg at 24 h intervals), recording rate of ductal closure, need for additional treatment, side-effects and clinical course",1,0,0,1,0
"The efficacy of the pharmacological treatment was similar in the two groups (56/81, 69% INDO; 69/94, 73% IBU)",0,0,0,0,0
"Patients treated with INDO showed a significant increase in serum creatinine (89 +/- 24 versus 82 +/- 20 mmol/l, P = 0.03) and a near-significant tendency for a lower fractional excretion of sodium (3 +/- 3 versus 4 +/- 2%, P = 0.08); moreover, 12/81 (15%) INDO patients versus 1/94 (1%) IBU patients became oliguric (< 1 ml/kg per h) during treatment (P = 0.017).",0,0,0,0,0
"Conclusion: Our findings confirm that, by comparison with indomethacin, ibuprofen has fewer effects on renal function in terms of urine output and fluid retention, with much the same efficacy and safety in closing patent ductus arteriosus in preterm infants with respiratory distress syndrome",0,0,0,0,0
"In particular, no increased incidence of intracranial haemorrhage was observed after ibuprofen treatment.",0,0,0,0,0
A comparison of ibuprofen and indomethacin for closure of patent ductus arteriosus,0,0,0,0,0
Background: Indomethacin is the conventional treatment for hemodynamically important patent ductus arteriosus in preterm infants,0,0,0,0,0
"However, its use is associated with various side effects",0,0,0,0,0
"In a prospective study, we compared ibuprofen and indomethacin with regard to efficacy and safety for the early treatment of patent ductus arteriosus in preterm infants.",0,0,0,0,0
"Methods: We studied 148 infants (gestational age, 24 to 32 weeks) who had the respiratory distress syndrome and an echocardiographically confirmed, hemodynamically important patent ductus arteriosus",0,0,0,0,0
"The infants were randomly assigned at five neonatal intensive care centers to receive three intravenous doses of either indomethacin (0.2 mg per kilogram of body weight, given at 12-hour intervals) or ibuprofen (a first dose of 10 mg per kilogram, followed at 24-hour intervals by two doses of 5 mq per kilogram each), starting on the third day of life",1,0,0,1,0
"The rate of ductal closure, the need for additional treatment, side effects, complications, and the infants' clinical course were recorded.",0,0,0,0,0
"Results: The rate of ductal closure was similar with the two treatments: ductal closure occurred in 49 of 74 infants given indomethacin (66 percent), and in 52 of 74 given ibuprofen (70 percent) (relative risk, 0.94; 95 percent confidence interval, 0.76 to 1.17; P=0.41)",0,0,0,0,0
The numbers of infants who needed a second pharmacologic treatment or surgical ductal ligation did not differ significantly between the two groups,0,0,0,0,0
Oliguria occurred in 5 infants treated with ibuprofen and in 14 treated with indomethacin (P=0.03),0,0,0,0,0
There were no significant differences with respect to other side effects or complications.,0,0,0,0,0
Conclusions: Ibuprofen therapy on the third day of life is as efficacious as indomethacin for the treatment of patent ductus arteriosus in preterm infants with the respiratory distress syndrome and is significantly less likely to induce oliguria.,0,0,0,0,0
Treatment of patent ductus arteriosus with ibuprofen,0,0,0,0,0
AIM—To evaluate the efficiency and side effects of ibuprofen for the early treatment of patent ductus arteriosus (PDA)and compare it with indomethacin.,0,0,0,0,0
"METHODS—Forty preterm infants with gestational ages of less than 33 weeks, with respiratory distress syndrome (RDS) and echocardiographically confirmed PDA, were randomly assigned at days 2 to 3 of life to receive either intravenous indomethacin 3 × 0.2 mg/kg at 12 hour intervals or intravenous ibuprofen 1 × 10 mg/kg, followed by 5 mg/kg 24 and 48 hours later.",1,0,0,1,0
RESULTS—PDA closed in 15 of 20 patients from the indomethacin group (75%) and in 16 of 20 (80%) from the ibuprofen group,0,0,0,0,0
"Seven patients (three indomethacin, four ibuprofen) required a second treatment with indomethacin and in five (three in the indomethacin group and two in the ibuprofen group) the duct was ultimately ligated",0,0,0,0,0
Ibuprofen patients had a better urinary output and showed no increase in serum creatinine concentrations compared with the indomethacin group,0,0,0,0,0
Ibuprofen was not associated with any other side effect.,0,0,0,0,0
CONCLUSIONS—Ibuprofen treatment seems to be as efficient as indomethacin in closing PDA on the third day of life in preterm infants with respiratory distress syndrome and seems to have fewer renal side effects.,0,0,0,0,0
Oral ibuprofen and indomethacin for treatment of patent ductus arteriosus in premature infants: a randomized trial at Ramathibodi Hospital,1,0,0,0,0
Background: Ibuprofen given intravenously to premature newborn infants is a proven treatment for patent ductus arteriosus (PDA),0,0,0,0,0
The efficacy of ibuprofen is comparable to indomethacin in many clinical trials with fewer renal side effects,0,0,0,0,0
"However, the intravenous form of ibuprofen is not available in Thailand, whereas, the oral suspension form is widely used for antipyretic treatment in children",0,0,0,0,0
"Therefore, the authors investigated the possibilities of using oral ibuprofen for the treatment of PDA in premature newborn infants.",0,0,0,0,0
Objective: To assess whether oral ibuprofen at 10 mg/kg/dose daily for 3 days was as effective as indomethacin to treat symptomatic PDA in premature infants and to compare the side effects of oral ibuprofen to indomethacin.,0,0,0,0,0
"The rates of ductal closure, infants' clinical courses, side effects and complications were recorded.",0,0,0,0,0
"Results: Birth weight, gestational age, gender, age onset and number of infants who had respiratory distress syndrome were similar in both groups, PDA was closed in 7 of 9 infants given ibuprofen (78%) and in 8 of 9 infants given indomethacin (89%) (p > 0.05)",0,0,0,0,0
Subjects and method: Eighteen premature infants with gestational ages less than 34 weeks born at Ramathibodi Hospital who developed symptomatic PDA were randomly assigned to receive three doses of either indomethacin (oral or intravenous administration 0.2 mg/kg/dose for three doses given at 12 hourly intervals or oral ibuprofen (10 mg/kg/dose for three doses given at 24 hourly intervals),1,0,0,1,0
The mean plasma concentration of ibuprofen was 28.05 microg/ml at 1 hour after the third dose,0,0,0,0,0
Neonates in the ibuprofen group had more urine output,0,0,0,0,0
"However, the increment of serum BUN and creatinine were not significantly different in both groups",0,0,0,0,0
"There were no significant differences in duration of ventilator support as well as number of patients with bronchopulmonary dysplasia, intraventricular hemorrhage, necrotizing enterocolitis and death in both groups.",0,0,0,0,0
Conclusion: Oral ibuprofen therapy is as effective as indomethacin for the treatment of PDA in premature infants and seems to have fewer renal side effects.,0,0,0,0,0
Helium-oxygen versus air-oxygen noninvasive pressure support in decompensated chronic obstructive disease: A prospective multi-center study,0,0,0,0,0
"Objective: To study whether noninvasive pressure support ventilation (NIPSV) with helium/oxygen (He/oxygen), which can reduce dyspnea, PaCO2, and work of breathing more than NIPSV with air/oxygen in decompensated chronic obstructive pulmonary disease, could have beneficial consequences on outcome and hospitalization costs.",0,0,0,0,0
"Design: Prospective, randomized, multicenter study.",1,0,0,0,0
Setting: Intensive care units of three tertiary care university hospitals.,0,0,0,0,0
Patients: All patients with chronic obstructive pulmonary disease admitted to the intensive care units for NIPSV during a 24-month period.,0,0,0,0,0
Interventions: Patients were randomized to NIPSV with air/oxygen or He/oxygen,1,0,0,0,0
"NIPSV settings, number of daily trials, decision to intubate, and intensive care unit and hospital discharge criteria followed standard practice guidelines.",0,0,0,0,0
"Results: A total of 123 patients (male/female ratio, 71:52; age, 71 +/- 10 yrs, Acute Physiology and Chronic Health Evaluation II, 17 +/- 4) were included",0,0,0,0,0
Intubation rate (air/oxygen 20% vs,0,0,0,0,0
He/oxygen 13%) and length of stay in the intensive care unit (air/oxygen 6.2 +/- 5.6 vs,0,0,0,0,0
He/oxygen 5.1 +/- 4 days) were comparable,0,0,0,0,0
The post-intensive care unit hospital stay was lower with He/oxygen (air/oxygen 19 +/- 12 vs,0,0,0,0,0
"He/oxygen 13 +/- 6 days, p < .002)",0,0,0,0,0
"Cost of NIPSV gases was higher with He/oxygen, but total hospitalization costs were lower by $3,348 per patient with He/oxygen",0,0,0,0,0
No complications were associated with the use of He/oxygen.,0,0,0,0,0
"Conclusion: He/oxygen did not significantly reduce intubation rate or intensive care unit stay, but hospital stay was shorter and total costs were lower",0,0,0,0,0
He/oxygen NIPSV can be safely administered and could prove to be a cost-effective strategy.,0,0,0,0,0
Helium/oxygen mixture reduces the work of breathing at the end of the weaning process in patients with severe chronic obstructive pulmonary diseas,0,0,0,0,0
Objective: To test the hypothesis that helium/oxygen mixture can reduce the work of breathing at the end of the weaning process in patients with chronic obstructive pulmonary disease.,0,0,0,0,0
"Design: Prospective, randomized, crossover study.",1,0,0,0,0
Setting: Two medical intensive care units at two university tertiary care centers.,0,0,0,0,0
It was possible to repeat the study after extubation in five patients.,0,0,0,0,0
"Measurements and main results: Before extubation, the helium/oxygen mixture induced no significant variation in the breathing pattern",0,0,0,0,0
Patients: Thirteen patients with chronic obstructive pulmonary disease evaluated just before and after extubation.,0,0,0,0,0
"Interventions: Helium/oxygen and air/oxygen mixtures were administered sequentially, for 20 mins each, in a randomized order, just before extubation",1,0,0,0,0
"By contrast, it reduced the work of breathing from 1.442 +/- 0.718 J/L (mean +/- sd) to 1.133 +/- 0.500 J/L (p <.05)",0,0,0,0,0
This reduction was explained mainly by a reduction in the resistive component of the work of breathing from 0.662 +/- 0.376 to 0.459 +/- 0.256 J/L (p <.01),0,0,0,0,0
We also observed a slight reduction in the intrinsic positive end-expiratory pressure from 2.9 +/- 2.1 cm H(2)O to 2.1 +/- 1.8 cm H(2)O (p <.05),0,0,0,0,0
Similar results were also observed after extubation in five patients in whom the repetition of the study was possible.,0,0,0,0,0
"Conclusions: In spontaneously breathing intubated patients with chronic obstructive pulmonary disease recovering from an acute exacerbation, helium/oxygen mixture reduces the work of breathing as well as intrinsic positive end-expiratory pressure without modifying the breathing pattern.",0,0,0,0,0
Noninvasive ventilation with Helium-oxygen in acute exacerbation of chronic obstructive pulmonary disease,0,0,0,0,0
The use of helium-oxygen (HeO(2)) was tested in combination with noninvasive ventilation (NIV) in 10 patients with acute exacerbation of chronic obstructive pulmonary disease (COPD),0,0,0,0,0
"Effort to breathe as assessed by the respiratory muscle pressure-time index (PTI), work of breathing (WOB), and gas exchange were the main endpoints",0,0,0,0,0
"Results of NIV-HeO(2) were compared with those obtained with standard NIV (AirO(2)), at two levels of pressure-support ventilation (PSV), 9 +/- 2 cm H(2)O and 18 +/- 3 cm H(2)O",0,0,0,0,0
Significant reductions in PTI were observed between HeO(2) and AirO(2) at both the low PSV level (n = 9; 160 +/- 58 versus 198 +/- 78 cm H(2)O/s/ min; p < 0.05) and the high PSV level (n = 10; 100 +/- 45 versus 150 +/- 82 cm H(2)O/s/min; p < 0.01),1,0,0,0,0
"WOB also differed significantly between HeO(2) and AirO(2) (7.8 +/- 4.1 versus 10.9 +/- 6.1 J/min at the low PSV level, p < 0.05; and 5.7 +/- 3.3 versus 9.2 +/- 5",0,0,0,0,0
"J/min, p < 0.01 at the high PSV level)",0,0,0,0,0
"HeO(2) reduced Pa(CO(2)) at both the low PSV level (61 +/- 13 versus 64 +/- 15 mm Hg; p < 0.05) and the high PSV level (56 +/- 13 versus 58 +/- 14 mm Hg; p < 0.05), without significantly changing breathing pattern or oxygenation",0,0,0,0,0
We conclude that use of HeO(2) during NIV markedly enhances the ability of NIV to reduce patient effort and to improve gas exchange.,0,0,0,0,0
Randomized trial of the use of heliox as a driving gas for updraft nebulization of bronchodilators in the emergent treatment of acute exacerbation of chronic obstructive pulmonary disease,1,0,0,0,0
Objective: To determine whether the bronchodilator effects of albuterol and ipratropium bromide are greater if updraft nebulization is driven by 80% helium and 20% oxygen (HELIOX) than if driven by compressed room air (AIR) during the treatment of an acute exacerbations of chronic obstructive pulmonary disease (COPD).,0,0,0,0,0
Setting: The emergency department of a 750-bed inner-city community hospital.,0,0,0,0,0
"Methods: Over a 12-month period, a convenience sample of 50 normoxic patients presenting with signs and symptoms of an acute exacerbation of COPD were prospectively randomized to receive either HELIOX or AIR as the driving gas for updraft nebulization of a mixture of albuterol 2.5 mg and ipratropium bromide 0.5 mg",1,0,0,1,0
"Additional aerosol treatments with albuterol 2.5 mg were given at 20, 40, and 120 mins after randomization using the assigned gas",1,0,0,0,0
Spirometry was obtained while breathing room air before the first treatment (baseline) and at 1 hr and 2 hrs after the initiation of treatment,0,0,0,0,0
The primary measure of efficacy was the change in percent of predicted forced expiratory volume in 1 sec (FEV1) over the treatment period,0,0,0,0,0
A secondary measure of efficacy was the change in percentage of predicted forced expiratory flow after 25% to 75% of vital capacity had been expelled (FEF25-75).,0,0,0,0,0
Results: Twenty-five patients were randomized to each treatment group,1,0,0,0,0
"Three patients (1 HELIOX, 2 AIR) were unable to complete the study",0,0,1,0,0
"The baseline FEV1was 44% (95% confidence interval, 35% to 52%) of predicted in the HELIOX group and 39 (31% to 46%) of predicted in the AIR group",0,0,0,0,0
There were no adverse outcomes observed in either the HELIOX group or the AIR group,0,0,0,0,0
"There were no significant differences in the change of FEV1 between the two groups by either the 1 hr or 2 hr time point (1 hr, HELIOX + 10% [7% to 13%], AIR + 9% [5% to 13%]; 2 hr HELIOX + 10% [6% to 15%], AIR + 10% [6% to 14%])",0,0,0,0,0
The improvement in FEF25-75 was significantly greater in the HELIOX group than in the AIR group at both the 1 hr time point (HELIOX + 14% [7% to 22%] vs,0,0,0,0,0
"AIR + 7% [3% to 10%], p = .05) and at the 2 hr time point (HELIOX + 15% [8% to 21%] vs",0,0,0,0,0
"AIR + 7% [4% to 11%], p = .05).",0,0,0,0,0
Conclusion: Use of HELIOX as a driving gas for the updraft nebulization of bronchodilators during the first 2 hrs of treatment of an acute COPD exacerbation failed to improve FEV1 faster than the use of AIR,0,0,0,0,0
The faster improvement in FEF25-75 during the first 2 hrs of treatment was small and of uncertain clinical significance.,0,0,0,0,0
Effects of Helium-oxygen on intrinsic positive end-expiratory pressure in intubated and mechanically ventilated patients with severe chronic obstructive pulmonary disease,0,0,0,0,0
"Objective: To test the hypothesis that replacing 70:30 nitrogen: oxygen (Air-O2) with 70:30 helium:oxygen (He-O2) can decrease dynamic hyperinflation (""intrinsic"" positive end-expiratory pressure) in mechanically ventilated patients with chronic obstructive pulmonary disease (COPD), and to document the consequences of such an effect on arterial blood gases and hemodynamics.",0,0,0,0,0
"Design: Prospective, interventional study.",0,0,0,0,0
"Setting: Medical intensive care unit, university tertiary care center.",0,0,0,0,0
"Patients: Twenty-three intubated, sedated, paralyzed, and mechanically ventilated patients with COPD enrolled within 36 hrs after intubation.",0,0,0,0,0
"Interventions: Measurements were taken at the following time points, all with the same ventilator settings: a) baseline; b) after 45 mins with He-O2; c) 45 mins after return to Air-O2",0,0,0,0,0
The results were then compared to those obtained in a test lung model using the same ventilator settings,0,0,0,0,0
MAIN RESULTS (MEAN + SD): Trapped lung volume and intrinsic positive end-expiratory pressure decreased during He-O2 ventilation (215+/-125 mL vs,0,0,0,0,0
99+/-15 mL and 9+/-2.5 cm H2O vs,0,0,0,0,0
"5+/-2.7 cm H2O, respectively; p < .05)",0,0,0,0,0
"Likewise, peak and mean airway pressures declined with He-O2 (30+/-5 cm H2O vs",0,0,0,0,0
25+/-6 cm H2O and 8+/-2 cm H2O vs,0,0,0,0,0
"7+/-2 cm H2O, respectively; p < .05)",0,0,0,0,0
These parameters all rose to their baseline values on return to Air-O2 (p < .05 vs,0,0,0,0,0
values during He-O2),0,0,0,0,0
These results were in accordance with those obtained in the test lung model,0,0,0,0,0
"There was no modification of arterial blood gases, heart rate, or mean systemic arterial blood pressure",0,0,0,0,0
"In 12/23 patients, a pulmonary artery catheter was in place, allowing hemodynamic measurements and venous admixture calculations",0,0,0,0,0
"Switching to He-O2 and back to Air-O2 had no effect on pulmonary artery pressures, right and left ventricular filling pressures, cardiac output, pulmonary and systemic vascular resistance, or venous admixture.",0,0,0,0,0
"Conclusion: In mechanically ventilated COPD patients with intrinsic positive end-expiratory pressure, the use of He-O2 can markedly reduce trapped lung volume, intrinsic positive end-expiratory pressure, and peak and mean airway pressures",0,0,0,0,0
No effect was noted on hemodynamics or arterial blood gases,0,0,0,0,0
"He-O2 might prove beneficial in this setting to reduce the risk of barotrauma, as well as to improve hemodynamics and gas exchange in patients with very high levels of intrinsic positive end-expiratory pressure.",0,0,0,0,0
Beneficial effects of Helium :oxygen versus air :oxygen noninvasive pressure support in patients with decompensated chronic obstructive pulmonary disease,0,0,0,0,0
"Objective: To test the hypothesis that, in decompensated chronic obstructive pulmonary disease (COPD), noninvasive pressure support ventilation using 70:30 helium:oxygen instead of 70:30 air:oxygen could reduce dyspnea and improve ventilatory variables, gas exchange, and hemodynamic tolerance.",0,0,0,0,0
"Design: Prospective, randomized, crossover study.",1,0,0,0,0
"Setting: Medical intensive care unit, university tertiary care center.",0,0,0,0,0
Patients: Nineteen patients with severe COPD (forced 1-sec expiratory volume of 0.83+/-0.3 l) hospitalized in the intensive care unit for noninvasive pressure support ventilation after initial stabilization with noninvasive pressure support for no more than 24 hrs after intensive care unit admission.,0,0,0,0,0
Interventions: Noninvasive pressure support ventilation was administered in the following randomized crossover design: a) 45 min with air:oxygen or helium:oxygen; b) no ventilation for 45 min; and c) 45 min with air:oxygen or helium:oxygen.,1,0,0,1,0
Measurements and main results: Air:oxygen and helium:oxygen decreased respiratory rate and increased tidal volume and minute ventilation,0,0,0,0,0
Helium:oxygen decreased inspiratory time,0,0,0,0,0
"Both gases increased total respiratory cycle time and decreased the inspiratory/total time ratio, the reduction in the latter being significantly greater with helium:oxygen",0,0,0,0,0
Peak inspiratory flow rate increased more with helium:oxygen,0,0,0,0,0
"PaO2 increased with both gases, whereas PaCO2 decreased more with helium:oxygen (values shown are mean+/-SD) (52+/-6 torr [6.9+/-0.8 kPa] vs",0,0,0,0,0
55+/-8 torr [7.3+/-1.1 kPa] and 48+/-6 torr [6.4+/-0.8 kPa] vs,0,0,0,0,0
"54+/-7 torr [7.2+/-0.9 kPa] for air:oxygen and helium:oxygen, respectively; p<.05)",0,0,0,0,0
"When hypercapnia was severe (PaCO2 >56 torr [7.5 kPa]), PaCO2 decreased by > or =7.5 torr (1 kPa) in six of seven patients with helium:oxygen and in four of seven patients with air:oxygen (p<.01)",0,0,0,0,0
Dyspnea score (Borg scale) decreased more with helium:oxygen than with air:oxygen (3.7+/-1.6 vs,0,0,0,0,0
4.5+/-1.4 and 2.8+/-1.6 vs,0,0,0,0,0
"4.6+/-1.5 for air:oxygen and helium:oxygen, respectively; p<.05)",0,0,0,0,0
Mean arterial blood pressure decreased with air:oxygen (76+/-12 vs,0,0,0,0,0
82+/-14 mm Hg; p<.05) but remained unchanged with helium:oxygen.,0,0,0,0,0
"Conclusion: In decompensated COPD patients, noninvasive pressure support ventilation with helium:oxygen reduced dyspnea and PaCO2 more than air:oxygen, modified respiratory cycle times, and did not modify systemic blood pressure",0,0,0,0,0
These effects could prove beneficial in COPD patients with severe acute respiratory failure and might reduce the need for endotracheal intubation.,0,0,0,0,0
Helium-oxygen breathing in severe COPD,0,0,0,0,0
The effect of breathing helium-oxygen (He-O2) mixtures was evaluated in 15 patients with severe chronic obstructive pulmonary disease (COPD),0,0,0,0,0
Gas exchange was assessed during quiet breathing at rest before and after 15 minutes of breathing 80 percent He-20 percent O2 mixtures in all patients,0,0,0,0,0
"Functional residual capacity (FRC) determined during argon (Ar) washing studies fell significantly while breathing He-O2, but we did not find significant changes in minute ventilation, tidal volume, respiratory frequency, or inspiratory or expiratory timing",0,0,0,0,0
Eleven patients showed decreases in arterial PCO2 and CO2 excretion during resting breathing on He-O2,0,0,0,0,0
Expiratory flows were increased at a given lung volume during He-O2 breathing as expected,0,0,0,0,0
"Apparently, mechanical work of breathing was decreased in patients with severe COPD while breathing He-O2, leading to a reduction in VCO2 and improvement in overall alveolar ventilation",0,0,0,0,0
These findings lend support to the therapeutic use of He-O2 under some conditions in patients with severe COPD.,0,0,0,0,0
Tranexamic acid in upper gastrointestinal haemorrhage,0,0,0,0,0
"In a double-blind trial in patients with bleeding from the upper gastrointestinal tract, those whose source of bleeding was distal to the gastro-œsophageal junction and whose barium-meal examination was negative benefited from oral tranexamic acid ('Cyclokapron') (1·5 g., eight-hourly)",0,1,0,0,0
"The volume of blood required for retransfusion was less in the treated group, especially in those patients with a negative barium-meal examination",0,0,0,0,0
"These findings are compatible with the concept of a fibrinolytic component in upper gastrointestinal bleeding, which may be of particular importance when bleeding is due to acute superficial erosions.",0,0,0,0,0
Tranexamic acid and upper gastrointestinal haemorrhage--a double-blind trial,0,1,0,0,0
The efficacy of antifibrinolytic therapy in the management of acute upper gastrointestinal haemorrhage has been investigated in a double-blind clinical trial,0,1,0,0,0
"Two-hundred patients were studied using tranexamic acid, a potent antifibrinolytic agent",0,0,0,0,0
"Of these, 103 were in the treatment group and 97 in the control group",0,0,0,0,0
"Patients were analysed to determine severity of initial blood loss, transfusion requirements, together with the incidence of recurrent bleeding, surgical intervention, and death",0,0,0,0,0
"Final diagnosis as to the site of bleeding was arrived at using endoscopy, barium studies, and the findings at operation and necropsy",0,0,0,0,0
"The groups were well matched as regards severity of initial haemorrhage, age, sex, aetiological diagnosis, and precipitating factors",0,0,0,0,0
A significant difference was observed in the requirement for surgical intervention to control continuing or recurrent haemorrhage,0,0,0,0,0
Twenty-three of 97 in the control group and seven of 103 in the treatment group required surgery,0,0,0,0,0
There appeared to be a reduction in the transfusion rate after the first three days of hospitalization in the treatment group,0,0,0,0,0
There were no significant differences in mortality or in side-effects between the two groups.,0,0,0,0,0
Tranexamic acid in massive haemorrhage from the upper gastrointestinal tract: a double-blind study,0,1,0,0,0
"In a double-blind trial of tranexamic acid in massive upper gastrointestinal haemorrhage, 76 patients were treated with the active drug and 73 patients with placebo",0,1,0,0,0
"The doses were 1 g intravenously six times daily for a maximum of 3 days, followed by 1.5 g orally four times daily for a maximum of 4 days",0,0,0,0,0
"The treatment group and the placebo group were comparable with respect to mean age, diagnoses and laboratory tests but differed slightly with respect to sex and alcohol consumption",0,0,0,0,0
"The transfusion requirement in the treatment group was less than in the placebo group during the first days after admission, the difference being significant on the second day after admission",0,0,0,0,0
Ten patients in the treatment group and 18 patients in the placebo group were operated on,0,0,0,0,0
Eleven patients in the treatment group and 12 patients in the placebo group died,0,0,0,0,0
In the tranexamic-acid-treated group fewer operations were performed and significantly less blood was needed,0,0,0,0,0
"It therefore seems highly likely that tranexamic acid has a beneficial effect, although small.",0,0,0,0,0
Local inhibition of the fibrinolytic system in patients with massive upper gastrointestinal hemorrhage,0,0,0,0,0
The effect or oral tranexamic acid on massive upper gastrointestinal hemorrhage was evaluated in a randomized double-blind study,1,1,0,0,0
"Totally 50 patients entered the trial and seven were excluded, leaving 22 placebo treated and 21 tranexamic acid treated for analysis",0,0,1,0,0
"The groups were comparable regarding sex, age, diagnosis, and initial laboratory data",0,0,0,0,0
Transfusions requirements and operation frequency did not differ,0,0,0,0,0
Mortality was slightly reduced and death delayed in tranexamic acid treated patients.,0,0,0,0,0
Cimetidine and tranexamic acid in the treatment of acute upper-gastrointestinal-tract bleedin,0,0,0,0,0
We studied the effects of tranexamic acid (an antifibrinolytic agent) and cimetidine on acute upper-gastrointestinal-tract bleeding in a double-blind randomized placebo-controlled trial in 775 patients with hematemesis or melena or both,1,1,0,0,0
"Mortality was significantly reduced in patients receiving either tranexamic acid (mortality, 6.3 per cent) or cimetidine (7.7 per cent), as compared with patients receiving placebo (13.5 per cent) (P = 0.0092 for tranexamic acid vs",0,0,0,0,0
"placebo, P = 0.045 for cimetidine vs",0,0,0,0,0
placebo),0,0,0,0,0
"Ninety-nine patients were withdrawn before the code was broken, mainly because their primary illness was considered not to be due to acute upper-gastrointestinal-tract bleeding",0,0,1,0,0
"Mortality among those withdrawn was high (22 per cent), and their exclusion reduced death rates to 4 per cent in those given tranexamic acid, 8 per cent in those given cimetidine, and 11 per cent in those given placebo (P = 0.0072 for tranexamic acid vs",0,0,1,0,0
"placebo, P greater than 0.50 for cimetidine vs",0,0,0,0,0
placebo),0,0,0,0,0
The reduced mortality associated with tranexamic acid was detectable at both participating hospitals and in most of the main subgroups of patients classified according to site of bleeding,0,0,0,0,0
"However, treatment with this agent was not associated with any decrease in the rate of rebleeding or the need for operation.",0,0,0,0,0
Tranexamic acid as an aid to reducing blood transfusion requirements in gastric and duodenal bleeding,0,0,0,0,0
A prospective randomised double blind study examined the effect of the antifibrinolytic drug tranexamic acid compared with placebo in 154 patients bleeding from verified benign lesions in the stomach or duodenum or both,1,1,0,0,0
Three out of 72 patients receiving tranexamic acid underwent emergency surgery compared with 15 out of 82 given placebo (p = 0.010),0,0,0,0,0
Nineteen patients receiving placebo rebled during their admission as compared with 10 in the active treatment group (p = 0.097),0,0,0,0,0
Blood transfusion requirements were significantly reduced by tranexamic acid (p = 0.018),0,0,0,0,0
"Side effects occurred in six patients, of which an uncomplicated deep venous thrombosis was the most severe",0,0,0,0,0
Tranexamic acid reduces the blood transfusion requirement and need for emergency surgery in patients bleeding from a benign gastric or duodenal lesion.,0,0,0,0,0
Oral dexamethasone in the treatment of croup: 0.15 mg/kg versus 0.3 mg/kg versus 0.6 mg/kg,0,0,0,0,0
"The objective of this study was to compare the efficacy of a single dose of oral dexamethasone of varying sizes in 120 children hospitalized with croup in two sequential double blind, randomized, controlled clinical trials (Trials A and B)",1,1,0,0,0
The study was conducted in the Emergency Department Observation Ward of a tertiary pediatric hospital,0,0,0,0,0
One hundred and twenty children (age range 6 to 160 months) hospitalized with croup participated,0,0,0,0,0
Baseline characteristics for the two groups in each trial were similar,0,0,0,0,0
In Trial A 60 children received either 0.6 or 0.3 mg/kg dexamethasone syrup; in Trial B 60 children received either 0.3 or 0.15 mg/ kg dexamethasone syrup,0,0,0,0,0
"Duration of hospitalization, reduction in croup scores, and adrenaline usage were evaluated",0,0,0,0,0
"Median duration of hospitalization was similar for children in Trial A (7 and 8 hr), and in Trial B (9 and 9 hr)",0,0,0,0,0
Croup scores following treatment did not differ and were significantly lower than initial scores for all groups and in each trial,0,0,0,0,0
"Other outcome measures were similar for the two groups in each trial, including need for nebulized adrenaline, numbers of patients admitted to intensive care, rate of return to medical care with reoccurrence of croup, and readmission to hospital with croup following discharge from hospital",0,0,0,0,0
We conclude that oral dexamethasone in a dose of 0.15 mg/kg is as effective as 0.3 or 0.6 mg/kg in relieving symptoms and results in a similar duration of hospitalization in children with croup.,0,0,0,0,0
Aciclovir treatment of varicella in otherwise healthy children,0,0,0,0,0
Study objective: To determine whether acyclovir administered orally affects the duration and severity of varicella in otherwise normal children.,0,0,0,0,0
"Design: Randomized, placebo-controlled, double-blind trial",1,1,0,0,0
Setting: Patients' residence and university hospital clinic,0,0,0,0,0
Patients: One hundred five children between 5 and 16 years of age with laboratory-confirmed varicella entered the study,0,0,0,0,0
"Of the 102 who were included in the final analysis, 50 received acyclovir and 52 received placebo.",0,0,0,0,0
"Intervention: Placebo or acyclovir was given orally four times daily, for 5 to 7 days",0,0,0,0,0
"The acyclovir dose was adjusted as follows: 5 to 7 years of age, 20 mg/kg; 7 to 12 years, 15 mg/kg; and 12 to 16 years, 10 mg/kg.",0,0,0,0,0
"Measurements and main results: Acyclovir recipients, compared with the placebo group, defervesced sooner (median, 1 day vs 2 days; p = 0.001), experienced onset of cutaneous healing sooner, as reflected by a decrease in number of lesions (median, 3 days vs 2 days; p = 0.002), and had fewer skin lesions (median, 500 vs 336; p = 0.02)",0,0,0,0,0
Acyclovir did not significantly change the rate of complications of varicella (10% in the acyclovir group vs 13.5% among placebo subjects),0,0,0,0,0
Adverse drug effects were not observed,0,0,0,0,0
"Acyclovir recipients had lower geometric mean serum antibody titers to varicella-zoster virus than their placebo counterparts 4 weeks after the onset of illness, but antibody titers in both groups were similar 1 year later.",0,0,0,0,0
Conclusions: These results provide evidence that acyclovir is useful and well tolerated for treatment of varicella in otherwise healthy children.,0,0,0,0,0
Acyclovir treatment of varicella in otherwise healthy adolescents,0,0,0,0,0
The Collaborative Acyclovir Varicella Study Group,0,0,0,0,0
"Study objective: To determine whether orally administered acyclovir is of therapeutic benefit for varicella in otherwise healthy adolescents, and to compare the severity of the disease in adolescents with that in younger children.",0,0,0,0,0
"Design: Multicenter, randomized, placebo-controlled, double-blind trial.",1,1,0,0,0
Setting: Patients' homes and university hospital clinics.,0,0,0,0,0
Patients: Sixty-eight adolescents between 13 and 18 years of age with varicella entered the study,0,0,0,0,0
"Of the 62 adolescents with laboratory-confirmed varicella who were included in the final analysis, 31 received acyclovir and 31 received placebo.",0,0,0,0,0
"Interventions: Placebo or an 800 mg acyclovir tablet was given orally four times daily for 5 days, beginning within 24 hours of onset of rash.",0,0,0,0,0
"Measurements and main results: Acyclovir recipients had significant reductions in times to cessation of new lesion formation (p less than 0.001), maximum number of lesions (p = 0.019), and defervescence (p = 0.045)",0,0,0,0,0
"Mean constitutional illness score was significantly reduced on day 4 (0.5 vs 1.5, p = 0.05), as was the mean number of residual hypopigmented lesions present on 28-day follow-up examination (22.7 vs 92.7, p = 0.018)",0,0,0,0,0
"Two complications, both bacterial superinfections, occurred in placebo recipients",0,0,0,0,0
Adverse experiences and varicella-zoster virus antibody titers measured 28 days after enrollment were similar in both treatment groups,0,0,0,0,0
"Comparison of placebo recipients with children 2 to 12 years of age participating in a companion study indicated that varicella is more severe in adolescents: mean maximum total lesions (421 vs 347, p = 0.003), mean maximum constitutional illness score (3.1 vs 2.2, p = 0.032), and mean number of residual lesions (92.7 vs 33.2, p = 0.01) were all greater in the adolescent population.",0,0,0,0,0
Conclusions: Oral acyclovir therapy is safe and effective for treatment of varicella in otherwise healthy adolescents; this may be an appropriate subgroup for treatment with antiviral drugs because the disease is more severe in them than in younger children.,0,0,0,0,0
"Hands-on robotic unicompartmental knee replacement: a prospective, randomised controlled study of the acrobot system",1,0,0,0,0
"We performed a prospective, randomised controlled trial of unicompartmental knee arthroplasty comparing the performance of the Acrobot system with conventional surgery",1,0,0,0,0
A total of 27 patients (28 knees) awaiting unicompartmental knee arthroplasty were randomly allocated to have the operation performed conventionally or with the assistance of the Acrobot,1,0,0,0,0
"The primary outcome measurement was the angle of tibiofemoral alignment in the coronal plane, measured by CT",0,0,0,0,0
Other secondary parameters were evaluated and are reported,0,0,0,0,0
"All of the Acrobot group had tibiofemoral alignment in the coronal plane within 2 degrees of the planned position, while only 40% of the conventional group achieved this level of accuracy",0,0,0,0,0
"While the operations took longer, no adverse effects were noted, and there was a trend towards improvement in performance with increasing accuracy based on the Western Ontario and McMaster Universities Osteoarthritis Index and American Knee Society scores at six weeks and three months",0,0,0,0,0
The Acrobot device allows the surgeon to reproduce a pre-operative plan more reliably than is possible using conventional techniques which may have clinical advantages.,0,0,0,0,0
Evaluation of robotic cardiac surgery simulation training: A randomized controlled trial,1,0,0,0,0
Objective: To compare the currently available simulation training modalities used to teach robotic surgery.,0,0,0,0,0
"Methods: Forty surgical trainees completed a standardized robotic 10-cm dissection of the internal thoracic artery and placed 3 sutures of a mitral valve annuloplasty in porcine models and were then randomized to a wet lab, a dry lab, a virtual reality lab, or a control group that received no additional training",1,0,0,1,0
All groups trained to a level of proficiency determined by 2 expert robotic cardiac surgeons,0,0,0,0,0
All assessments were evaluated using the Global Evaluative Assessment of Robotic Skills in a blinded fashion.,0,0,0,0,0
Conclusions: We have completed the first randomized controlled trial to objectively compare the different training modalities of robotic surgery,1,0,0,0,0
Our data demonstrate the significant benefits of wet lab and virtual reality robotic simulation training and highlight key differences in current training methods,0,0,0,0,0
"This study can help guide training programs in investing resources in cost-effective, high-yield simulation exercises.",0,0,0,0,0
Clinicians entered baseline data via a telephone voice-activated or a secure web-based randomisation system,1,0,0,1,0
"After the system had recorded and checked the data, patients were allocated either immediate thrombolysis with 0·9 mg/kg of intravenous rt-PA to a maximum of 90 mg (10% bolus with the remainder over 1 h) or control treatment",0,0,0,0,0
The system would not accept patients with blood pressure or glucose levels outside protocol-defined criteria (appendix pp 4–5) or other data inconsistencies,0,0,0,0,0
"The system used a minimisation algorithm to achieve optimum balance for key prognostic factors (table 1), and from January, 2006, minimisation was additionally stratified by world region and then minimised on all the other key factors within regions.",0,0,0,0,0
"To be eligible to join the trial, participating hospitals had to have an organised system of stroke care",0,0,0,0,0
"Acute-care protocols were not specified by the trial, but had to include the components of effective stroke-unit care,19 including, soon after admission, intravenous access, monitoring of physiological variables, correction of any abnormalities, and where clinically appropriate, intravenous-fluid therapy",0,0,0,0,0
"All patients in the trial were to be treated within that organised system of stroke care, irrespective of treatment allocation",0,0,0,0,0
Patients allocated to the control group were to avoid treatment with rt-PA and received stroke care in the same clinical environment as those allocated to the rt-PA group,0,0,0,0,0
Both treatment groups had blood pressure monitored closely over the first 24 h.,0,0,0,0,0
"In the double-blinded phase, both groups were to avoid antiplatelet or anticoagulant therapy for 24 h",0,1,0,0,0
"In the open phase, patients allocated to the control group were to start aspirin immediately",0,0,0,0,0
"Blood pressure was managed in the same way in both treatment groups, according to local protocol",0,0,0,0,0
"Additionally, all centres were asked for their pretrial experience of thrombolysis for treatment of stroke, and if the centre had, before joining the trial, a protocol for open-label use of rt-PA and had treated at least three people in the 12 months before joining the trial, the centre was classed as experienced.",0,0,0,0,0
All patients had a CT or MRI brain scan before randomisation and a follow-up scan at 24–48 h. ,1,0,0,0,0
A repeat brain scan was required if the patient deteriorated neurologically or intracranial haemorrhage was suspected for any reason.,0,0,0,0,0
"Although CT scanning was preferred, MRI was allowed",0,0,0,0,0
"All scans were sent to the trial centre in Edinburgh for masked central rating of any signs of visible early ischaemia (presence and extent of hypo-attenuation, swelling, hyperattenuated artery), haemorrhage, and background brain changes (leukoaraiosis, atrophy, prior stroke lesions, non-stroke lesions) with validated rating methods.20–25 ",0,0,0,0,0
"Images were assessed with all original identifiers stripped from the record, and then viewed via a secure web-based image viewing system by an international panel of expert radiologists",0,0,0,0,1
All assessments were made masked to all patient details and treatment allocation.,0,0,0,0,1
Data on potential reports of any of these events were extracted from the trial database and presented to the adjudication committee who were masked to treatment allocation,0,0,0,0,1
"To avoid predictable alternation of treatment allocation, and thus potential loss of allocation concealment, patients were allocated with a probability of 0·80 to the treatment group that would minimise the difference between the groups on the key prognostic factors",0,0,0,0,1
Additional details of the procedures used in the double-blinded phase of the study are reported elsewhere,0,1,0,0,1
"The randomisation system informed local clinicians of the patients' unique trial identification number, and the weight-adjusted dose of drug or placebo in the double-blinded phase, or of the weight-adjusted drug dose among those allocated thrombolysis in the open phase, to be given as a 10% bolus with the remainder by an infusion over 1 h.",1,1,0,1,1
"With the exception of the 276 patients treated in the double-blinded phase of the trial, treatment was given openly and neither the patient nor the treating clinicians were masked. ",0,1,0,0,0
"Hospital staff completed an early outcome form at 7 days, death, or hospital discharge, whichever occured first, recording details of events occurring in hospital within 7 days, details of background treatments given and functional status",0,0,0,0,0
"6 months after randomisation, general practitioners (or hospital coordinators) were contacted by the IST-3 trial office staff to check that the patient was alive and inform them that they might be approached for follow-up",1,0,0,0,0
"If appropriate, the IST-3 trial office masked staff then mailed a postal questionnaire to patients to assess outcome",0,0,0,0,0
"Non-responders were contacted by telephone, and follow-up data was obtained by telephone interview",0,0,0,0,0
"In Italy and Austria, all follow-ups were done as telephone interviews by a clinician, who was masked to treatment allocation and was highly experienced in outcome assessment",0,0,0,0,0
"In Portugal, patients were followed up in clinic by clinicians not involved in the patients' initial treatment, again, masked to treatment allocation as far as possible",0,0,0,0,0
"To assess the durability of any treatment benefit beyond 6 months, patients recruited in the UK (and in other countries where appropriate funding had been obtained) were also followed up at 18 months",0,0,0,0,0
"All follow-up done by patient contact for these analyses ceased on March 31, 2012, but recording of deaths from national registries of deaths continues in UK, Norway, and Sweden.",0,0,0,0,0
Effect of Vocimagene Amiretrorepvec in Combination With Flucytosine vs Standard of Care on Survival Following Tumor Resection in Patients With Recurrent High-Grade Glioma: A Randomized Clinical Trial,1,0,0,0,0
Importance: New treatments are needed to improve the prognosis of patients with recurrent high-grade glioma.,0,0,0,0,0
Objective: To compare overall survival for patients receiving tumor resection followed by vocimagene amiretrorepvec (Toca 511) with flucytosine (Toca FC) vs standard of care (SOC).,0,0,0,0,0
"Design, setting, and participants: A randomized, open-label phase 2/3 trial (TOCA 5) in 58 centers in the US, Canada, Israel, and South Korea, comparing posttumor resection treatment with Toca 511 followed by Toca FC vs a defined single choice of approved (SOC) therapies was conducted from November 30, 2015, to December 20, 2019.",1,0,0,0,0
Patients received tumor resection for first or second recurrence of glioblastoma or anaplastic astrocytoma.,0,0,0,0,0
Interventions: Patients were randomized 1:1 to receive Toca 511/FC (n = 201) or SOC control (n = 202).,1,0,0,0,0
"For the Toca 511/FC group, patients received Toca 511 injected into the resection cavity wall at the time of surgery, followed by cycles of oral Toca FC 6 weeks after surgery.",0,0,0,0,0
"For the SOC control group, patients received investigators' choice of single therapy: lomustine, temozolomide, or bevacizumab.",0,0,0,0,0
Main outcomes and measures: The primary outcome was overall survival (OS) in time from randomization date to death due to any cause.,1,0,0,0,0
"Secondary outcomes reported in this study included safety, durable response rate (DRR), duration of DRR, durable clinical benefit rate, OS and DRR by IDH1 variant status, and 12-month OS.",0,0,0,0,0
"Results: All 403 randomized patients (median [SD] age: 56 [11.46] years; 62.5% [252] men) were included in the efficacy analysis, and 400 patients were included in the safety analysis (3 patients on the SOC group did not receive resection).",1,0,0,0,0
Final analysis included 271 deaths (141 deaths in the Toca 511/FC group and 130 deaths in the SOC control group).,0,0,0,0,0
The median follow-up was 22.8 months. ,0,0,0,0,0
"The median OS was 11.10 months for the Toca 511/FC group and 12.22 months for the control group (hazard ratio, 1.06; 95% CI 0.83, 1.35; P = .62).",0,0,0,0,0
The secondary end points did not demonstrate statistically significant differences.,0,0,0,0,0
The rates of adverse events were similar in the Toca 511/FC group and the SOC control group.,0,0,0,0,0
"Conclusions and relevance: Among patients who underwent tumor resection for first or second recurrence of glioblastoma or anaplastic astrocytoma, administration of Toca 511 and Toca FC, compared with SOC, did not improve overall survival or other efficacy end points.",0,0,0,0,0
"Treatment of primary Sjögren's syndrome with ianalumab (VAY736) targeting B cells by BAFF receptor blockade coupled with enhanced, antibody-dependent cellular cytotoxicity",0,0,0,0,0
"Objectives: To evaluate the efficacy and safety of ianalumab (VAY736), a B cell-depleting, B cell activating factor receptor-blocking, monoclonal antibody, in patients with active primary Sjögren's syndrome (pSS) in a double-blind, placebo-controlled, phase II, single-centre study.",0,1,0,0,0
"Methods: Patients with pSS, EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI) ≥6, were randomised to ianalumab single infusion at either 3 mg/kg (n=6), 10 mg/kg (n=12) or placebo (n=9).",1,0,0,1,0
"Outcomes were measured blinded at baseline and weeks 6, 12, 24, and unblinded at end of study (EoS) when B cell numbers had recovered. ",0,0,0,0,0
Laboratory-based measures included circulating leucocyte subsets and markers of B cell activity.,0,0,0,0,0
"Clinical outcomes included ESSDAI, EULAR Sjögren's Syndrome Patient Reported Index (ESSPRI), salivary flow rate, ocular staining score, physician global assessment and patient assessments of fatigue and general quality of life. ",0,0,0,0,0
"Results: A similar trend showing positive therapeutic effect by ianalumab was observed across the primary clinical outcome (ESSDAI) and all secondary clinical outcomes (ESSPRI, Multidimensional Fatigue Inventory, Short Form-36, global assessments by physician and patient) versus the placebo-treated group. ",0,0,0,0,0
Rapid and profound B cell depletion of long-lasting duration occurred after a single infusion of ianalumab at either dose.,0,0,0,0,0
"Serum Ig light chains decreased, with return to baseline levels at EoS.",0,0,0,0,0
Changes in some clinical outcomes persisted through to EoS in the higher dose group.,0,0,0,0,0
Adverse effects were largely limited to mild to moderate infusion reactions within 24 hours of ianalumab administration.,0,0,0,0,0
Conclusions: Overall results in this single-dose study suggest potent and sustained B cell depletion by ianalumab could provide therapeutic benefits in patients with pSS without major side effects.,0,0,0,0,0
Randomized Controlled Trial of Rituximab and Cost-Effectiveness Analysis in Treating Fatigue and Oral Dryness in Primary Sjögren's Syndrome,1,0,0,0,0
"Objective: To investigate whether rituximab, an anti-B cell therapy, improves symptoms of fatigue and oral dryness in patients with primary Sjögren's syndrome (SS).",0,0,0,0,0
"Methods: We conducted a multicenter, randomized, double-blind, placebo-controlled, parallel-group trial that included health economic analysis.",1,1,0,0,0
" Anti-Ro-positive patients with primary SS, symptomatic fatigue, and oral dryness were recruited from 25 UK rheumatology clinics from August 2011 to January 2014.",0,0,0,0,0
"Patients were centrally randomized to receive either intravenous (IV) placebo (250 ml saline) or IV rituximab (1,000 mg in 250 ml saline) in 2 courses at weeks 0, 2, 24, and 26, with pre- and postinfusion medication including corticosteroids.",1,0,0,1,0
"The primary end point was the proportion of patients achieving a 30% reduction in either fatigue or oral dryness at 48 weeks, as measured by visual analog scale.",0,0,0,0,0
"Other outcome measures included salivary and lacrimal flow rates, quality of life, scores on the European League Against Rheumatism (EULAR) Sjögren's Syndrome Patient Reported Index and EULAR Sjögren's Syndrome Disease Activity Index, symptoms of ocular and overall dryness, pain, globally assessed disease activity, and cost-effectiveness.",0,0,0,0,0
Results: All 133 patients who were randomized to receive placebo (n = 66) or rituximab (n = 67) were included in the primary analysis.,1,0,0,0,0
"Among patients with complete data, 21 of 56 placebo-treated patients and 24 of 61 rituximab-treated patients achieved the primary end point.",0,0,0,0,0
"After multiple imputation of missing outcomes, response rates in the placebo and rituximab groups were 36.8% and 39.8%, respectively (adjusted odds ratio 1.13 [95% confidence interval 0.50, 2.55]).",0,0,0,0,0
There were no significant improvements in any outcome measure except for unstimulated salivary flow.,0,0,0,0,0
" The mean ± SD costs per patient for rituximab and placebo were £10,752 ± 264.75 and £2,672 ± 241.71, respectively. ",0,0,0,0,0
"There were slightly more adverse events (AEs) reported in total for rituximab, but there was no difference in serious AEs (10 in each group).",0,0,0,0,0
Conclusion: The results of this study indicate that rituximab is neither clinically effective nor cost-effective in this patient population.,0,0,0,0,0
Treatment of primary Sjögren syndrome with rituximab: a randomized trial,1,0,0,0,0
Background: Primary Sjögren syndrome (pSS) is an autoimmune disorder characterized by ocular and oral dryness or systemic manifestations.,0,0,0,0,0
Objective: To evaluate efficacy and harms of rituximab in adults with recent-onset or systemic pSS.,0,0,0,0,0
"Design: Randomized, placebo-controlled, parallel-group trial conducted between March 2008 and January 2011.",1,1,0,0,0
"Study personnel (except pharmacists), investigators, and patients were blinded to treatment group.",0,1,0,0,1
Setting: 14 university hospitals in France.,0,0,0,0,0
"Patients: 120 patients with scores of 50 mm or greater on at least 2 of 4 visual analogue scales (VASs) (global disease, pain, fatigue, and dryness) and recent-onset (< 10 years) biologically active or systemic pSS.",0,0,0,0,0
Intervention: Randomization (1:1 ratio) to rituximab (1 g at weeks 0 and 2) or placebo.,1,0,0,1,0
Measurements: Primary end point was improvement of at least 30 mm in 2 of 4 VASs by week 24.,0,0,0,0,0
"Results: No significant difference between groups in the primary end point was found (difference, 1.0% [95% CI, -16.7% to 18.7%]). ",0,0,0,0,0
he proportion of patients with at least 30-mm decreases in at least two of the four VAS scores was higher in the rituximab group at week 6 (22.4% vs. 9.1%; P = 0.036).,0,0,0,0,0
"An improvement of at least 30 mm in VAS fatigue score was more common with rituximab at weeks 6 (P < 0.001) and 16 (P = 0.012), and improvement in fatigue from baseline to week 24 was greater with rituximab.",0,0,0,0,0
Adverse events were similar between groups except for a higher rate of infusion reactions with rituximab,0,0,0,0,0
Limitation: Low disease activity at baseline and a primary outcome that may have been insensitive to detect clinically important changes.,0,0,0,0,0
"Conclusion: Rituximab did not alleviate symptoms or disease activity in patients with pSS at week 24, although it alleviated some symptoms at earlier time points.",0,0,0,0,0
Remote ischemic conditioning improves cognition in patients with subcortical ischemic vascular dementia,0,0,0,0,0
"Background: Subcortical ischemic vascular dementia (SIVD) is very common among the older people, but has no approved treatment. ",0,0,0,0,0
Preclinical trials show that remote ischemic conditioning (RIC) reduces recurrence of ischemic stroke. ,0,0,0,0,0
We hypothesize that RIC may also be an effective therapy for patients with SIVD.,0,0,0,0,0
Methods: Thirty-seven consecutive SIVD cases were enrolled in this randomized control study.,1,0,0,0,0
Eighteen RIC patients underwent five brief cycles of conditioning (bilateral upper limb compression at 200 mmHg) followed by reperfusion twice daily over 6 consecutive months. ,0,0,0,0,0
"Nineteen control patients underwent the same process, but at a pressure of 60 mmHg which caused no restriction on the blood flow of the upper limb.",0,0,0,0,0
The primary outcome measures were changes in neuropsychological assessments.,0,0,0,0,0
"The secondary outcomes included the changes in high-sensitive C-reactive protein (hs-CRP) concentration, white matter lesion volume (WMLV), diffusion tension imaging (DTI) metrics of white matter. ",0,0,0,0,0
All data were collected at baseline and follow-up.,0,0,0,0,0
"Results: A significant treatment difference favoring RIC at 6 months was observed on performance of Hopkins Verbal Learning Test-Revised (HVLT-R), Controlled Oral Word Association Test (COWAT), Trail Making Test A and B (TMT-A & TMT-B), and Judgment of Line Orientation (JLO) (p < 0.05).",0,0,0,0,0
"The control group did not show much improvement after the treatment, and only with a slight change in HVLT-R and TMT-R (p < 0.05). Covariance analysis of efficacy between the two groups suggested that RIC patients performed better on JLO than control patients at the 6-month follow-up (RIC 23.10 vs. control 18.56; p = 0.013). ",0,0,0,0,0
"Although DTI metrics were comparable, Hs-CRP levels and WMLV in RIC patients showed a declining trend.",0,0,0,0,0
"Conclusions: Over the 6-month treatment period, we found that RIC was safe and effective for improving cognitive function in SIVD patients.",0,0,0,0,0
"Double-blind, randomized and controlled trial of EPI-743 in Friedreich's ataxia",1,1,0,0,0
Aim: To evaluate the safety and clinical effects of EPI-743 in Friedreich's ataxia patients. ,0,0,0,0,0
EPI-743 is a compound that targets oxidoreductase enzymes essential for redox control of metabolism,0,0,0,0,0
"Methods: We conducted a multicenter trial that evaluated EPI-743 during a 6-month placebo-controlled phase, followed by an 18-month open-label phase.",0,0,0,0,0
End points included low-contrast visual acuity and the Friedreich's Ataxia Rating Scale.,0,0,0,0,0
Results/conclusion: EPI-743 was demonstrated to be safe and well tolerated.,0,0,0,0,0
There were no significant improvements in key end points during the placebo phase.,0,0,0,0,0
"However, at 24 months, EPI-743 treatment was associated with a statistically significant improvement in neurological function and disease progression relative to a natural history cohort (p < 0.001).",0,0,0,0,0
One-year sustained efficacy of erenumab in episodic migraine: Results of the STRIVE study,0,0,0,0,0
Objective: To assess efficacy and tolerability of 1-year erenumab treatment in patients with episodic migraine.,0,0,0,0,0
Methods: Patients were randomized (n = 955; 1:1:1) during the 24-week double-blind treatment phase (DBTP) to monthly subcutaneous placebo or erenumab 70 or 140 mg. ,1,1,0,0,0
"At week 24, 845 patients were rerandomized (1:1) to erenumab 70 or 140 mg during the 28-week dose-blinded active-treatment phase (ATP).",0,1,0,0,0
"Monthly migraine days (MMD), achieving ≥50%, ≥75%, and 100% reduction in MMD, and safety/tolerability were assessed.",0,0,0,0,0
"Results: Mean MMD at DBTP baseline was 8.3. At week 52, mean changes (SE) from pre-DBTP baseline/week 24 (pre-ATP baseline) in MMD were -4.2 (0.2)/-1.1 (0.2) (70 mg) and -4.6 (0.2)/-1.8 (0.2) (140 mg) irrespective of treatment during the DBTP.",0,0,0,0,0
"For patients reducing dose from 140 (DBTP) to 70 mg (ATP), change in MMD from week 24 to 52 was -0.1 (0.3), and for those increasing from 70 (DBTP) to 140 mg (ATP), -1.8 (0.3). ",0,0,0,0,0
"At week 52, 61.0%, 38.5%, and 19.8% of patients on erenumab 70 mg, and 64.9%, 40.8%, and 21.2% on erenumab 140 mg, achieved ≥50%, ≥75%, and 100% reduction in MMD from DBTP baseline, respectively.",0,0,0,0,0
"Among erenumab-treated patients in DBTP who showed ≥50% reduction in MMD during the last 3 months of DBTP and completed ATP, 86% showed sustained responses at ≥50% during the last 3 months of ATP. ",0,0,0,0,0
Safety of erenumab in ATP was similar to DBTP; exposure-adjusted incidence rates of adverse events were similar for either dose.,0,0,0,0,0
"Conclusion: Over 52 weeks, erenumab provided sustained efficacy in episodic migraine; the safety profiles were similar between erenumab dose groups in the presence of dose blinding.",0,1,0,0,0
Randomized controlled trial on the influence of dietary intervention on epigenetic mechanisms in children with cow's milk allergy: the EPICMA study,1,0,0,0,0
Epigenetic mechanisms could drive the disease course of cow's milk allergy (CMA) and formula choice could modulate these pathways. ,0,0,0,0,0
We compared the effect of two different dietary approaches on epigenetic mechanisms in CMA children.,0,0,0,0,0
Randomized controlled trial on IgE-mediated CMA children receiving a 12-month treatment with extensively hydrolyzed casein formula containing the probiotic L.rhamnosus GG (EHCF + LGG) or with soy formula (SF). ,1,0,0,0,0
"At the baseline, after 6 and 12 months of treatment FoxP3 methylation rate and its expression in CD4+ T cells were assessed.",0,0,0,0,0
"At same study points IL-4, IL-5, IL-10, and IFN-γ methylation rate, expression and serum concentration, miRNAs expression were also investigated. 20 children (10/group) were evaluated.",0,0,0,0,0
"Baseline demographic, clinical and epigenetic features were similar in the two study groups. ",0,0,0,0,0
"t 6 and 12 months, EHCF + LGG group showed a significant increase in FoxP3 demethylation rate compared to SF group.",0,0,0,0,0
"At the same study points, EHCF + LGG group presented a higher increase in IL-4 and IL-5 and a higher reduction in IL-10 and IFN-γ DNA methylation rate compared to SF group.",0,0,0,0,0
"A different modulation of miR-155, -146a, -128 and -193a expression was observed in EHCF + LGG vs. SF. Dietary intervention could exert a different epigenetic modulation on the immune system in CMA children.",0,0,0,0,0
Activate: Randomized Clinical Trial of BCG Vaccination against Infection in the Elderly,1,0,0,0,0
BCG vaccination in children protects against heterologous infections and improves survival independently of tuberculosis prevention. ,0,0,0,0,0
The phase III ACTIVATE trial assessed whether BCG has similar effects in the elderly. ,0,0,0,0,0
"In this double-blind, randomized trial, elderly patients (n = 198) received BCG or placebo vaccine at hospital discharge and were followed for 12 months for new infections.",1,1,0,0,0
"At interim analysis, BCG vaccination significantly increased the time to first infection (median 16 weeks compared to 11 weeks after placebo). ",0,0,0,0,0
"The incidence of new infections was 42.3% (95% CIs 31.9%-53.4%) after placebo vaccination and 25.0% (95% CIs 16.4%-36.1%) after BCG vaccination; most of the protection was against respiratory tract infections of probable viral origin (hazard ratio 0.21, p = 0.013). ",0,0,0,0,0
No difference in the frequency of adverse effects was found. ,0,0,0,0,0
Data show that BCG vaccination is safe and can protect the elderly against infections.,0,0,0,0,0
"Larger studies are needed to assess protection against respiratory infections, including COVID-19 ",0,0,0,0,0
"Efficacy of individualized homeopathic treatment of insomnia: Double-blind, randomized, placebo-controlled clinical trial",1,1,0,0,0
"Background: Insomnia is the most common sleep-related complaint associated with impaired day-time functioning, reduced quality of life, increased morbidity and substantial societal cost. ",0,0,0,0,0
We evaluated whether individualized homeopathy (IH) could produce significant effect beyond placebo in treatment of insomnia.,0,0,0,0,0
"Methods: In this double-blind, randomized, placebo-controlled, two parallel arms trial, 60 patients were randomized to receive either IH/verum or control/placebo (1:1). ",1,1,0,0,0
"Patient-administered sleep diary (6 items; 1: latency to fall asleep, 2: minutes awake in middle of night, 3: minutes awake too early, 4: hours spent in bed, 5: total sleep time in hours, and 6: sleep efficiency) and Insomnia Severity Index (ISI) were taken as the primary and secondary outcomes respectively, measured at baseline, and after 3 months.",0,0,0,0,0
"Results: Five patients dropped out (verum: 2, control: 3). ",0,0,1,0,0
Intention to treat sample (n = 60) was analyzed. ,0,0,0,0,0
Trial arms were comparable at baseline.,0,0,0,0,0
"In the verum group, except sleep diary item 3 (P = 0.371), rest of the outcomes improved significantly (all P < 0.01).",0,0,0,0,0
"In the control group, there were significant improvements in diary item 6 and ISI score (P < 0.01) and just significant improvement in item 5 (P = 0.018).",0,0,0,0,0
"Group differences were significant for items 4, 5 and 6 (P < 0.01) and just significant (P = 0.014) for ISI score with moderate to large effect sizes; but non-significant (P > 0.01) for rest of the outcomes.",0,0,0,0,0
Conclusion: IH seemed to produce significantly better effect than placebo.,0,0,0,0,0
Rigorous trials and independent replications are warranted.,0,0,0,0,0
Effectiveness of a homeopathic complex medicine in infantile colic: A randomized multicenter study,1,0,0,0,0
Objectives: Infantile colic is a common benign disease occurring in early infancy that may have a great impact on family life. ,0,0,0,0,0
"In the present study, the effectiveness and safety of the complex homeopathic medicine Enterokind was compared with Simethicone for treating infantile colic.",0,0,0,0,0
"Design and setting: Current data were drawn from a prospective, multicenter, randomized, open-label, controlled clinical trial that was conducted in 2009 in 3 Russian outpatient clinics.",1,0,0,0,0
"Children received either Enterokind (Chamomilla D6, Cina D6, Colocynthis D6, Lac defloratum D6 and Magnesium chloratum D6) or Simethicone.",0,0,0,0,0
Data from infants ≤ 6 months with infantile colic are presented here.,0,0,0,0,0
Main outcome measures: The main outcomes assessments were the change of total complaints score (maximum 17 points) and total objective symptoms score (maximum 22 points) after 10 days of treatment.,0,0,0,0,0
Results: Data from 125 infants ≤ 6 months with infantile colic were analyzed.,0,0,0,0,0
"The differences in total complaints and objective symptoms scores between baseline and day 10, estimated from the ANCOVA model, were found to be highly significant (p < 0.0001; ITT) in favor of Enterokind, both for complaints (Δ=-2.38; 95% confidence interval (CI): [-2.87; -1.89]) and for objective symptoms (Δ=-2.07; 95% CI: [-2.65; -1.49]).",0,0,0,0,0
"1 adverse event (AE), vomiting, occurred under Enterokind and was rated to be unlikely related to it; 4 AEs occurred under Simethicone. ",0,0,0,0,0
All AEs were non-serious.,0,0,0,0,0
Conclusions: The current study indicates that Enterokind is an effective and safe homeopathic treatment for functional intestinal colic in infants ≤ 6 months.,0,0,0,0,0
A randomized controlled trial of the ketogenic diet in refractory childhood epilepsy,1,0,0,0,0
Objective: To evaluate the efficacy and tolerability of the ketogenic diet (KD) during the first 4 months of a randomized controlled trial (RCT) in refractory epilepsy patients aged 1-18 years.,1,0,0,0,0
"Methods: Children and adolescents with refractory epilepsy, not eligible for epilepsy surgery, were included. ",0,0,0,0,0
"Following 1 month at baseline, patients were randomized to either the KD or to care as usual (CAU).",1,0,0,0,0
Primary outcome is the proportion of patients with at least 50% reduction in seizure frequency at 4 months. ,0,0,0,0,0
"Secondary outcomes are mean percentage of baseline seizures, seizure severity, and side effects.",0,0,0,0,0
"Results: Fifty-seven patients were randomized; nine dropped out, leaving 48 for analysis (i.e., 26 KD, 22 CAU). ",1,0,1,0,0
"In an intention-to-treat analysis, 13 patients (50%) treated with the KD and four patients (18.2%) of the CAU group were responders.",0,0,0,0,0
"Mean seizure frequency at 4 months compared to baseline, after removal of two outliers in the KD group, was significantly lower (P = 0.024) in the KD group (56%) (95% CI: 36-76) than in the CAU group (99%) (95% CI: 65-133%).",0,0,0,0,0
Twice as many patients in the KD group had a relevant decrease in seizure severity score (P = 0.070),0,0,0,0,0
Patients treated with the KD had a significantly higher score for gastrointestinal symptoms (P = 0.021) without an increase in the total score of side effects.,0,0,0,0,0
Conclusions: This trial provides class I evidence that the KD is an effective therapy in children and adolescents with refractory epilepsy compared with CAU.,0,0,0,0,0
Most often reported side effects are gastrointestinal symptoms.,0,0,0,0,0
The study has been registered with the Netherlands Trial Registry (NTR2498).,0,0,0,0,0
Tocilizumab in Patients Hospitalized with Covid-19 Pneumonia,0,0,0,0,0
Background: Coronavirus disease 2019 (Covid-19) pneumonia is often associated with hyperinflammation. ,0,0,0,0,0
"Despite the disproportionate incidence of Covid-19 among underserved and racial and ethnic minority populations, the safety and efficacy of the anti-interleukin-6 receptor antibody tocilizumab in patients from these populations who are hospitalized with Covid-19 pneumonia are unclear.",0,0,0,0,0
Methods: We randomly assigned (in a 2:1 ratio) patients hospitalized with Covid-19 pneumonia who were not receiving mechanical ventilation to receive standard care plus one or two doses of either tocilizumab (8 mg per kilogram of body weight intravenously) or placebo. ,1,0,0,1,0
Site selection was focused on the inclusion of sites enrolling high-risk and minority populations. ,0,0,0,0,0
The primary outcome was mechanical ventilation or death by day 28.,0,0,0,0,0
"Results: A total of 389 patients underwent randomization, and the modified intention-to-treat population included 249 patients in the tocilizumab group and 128 patients in the placebo group; 56.0% were Hispanic or Latino, 14.9% were Black, 12.7% were American Indian or Alaska Native, 12.7% were non-Hispanic White, and 3.7% were of other or unknown race or ethnic group.",1,0,0,0,0
"The cumulative percentage of patients who had received mechanical ventilation or who had died by day 28 was 12.0% (95% confidence interval [CI], 8.5 to 16.9) in the tocilizumab group and 19.3% (95% CI, 13.3 to 27.4) in the placebo group (hazard ratio for mechanical ventilation or death, 0.56; 95% CI, 0.33 to 0.97; P = 0.04 by the log-rank test).",0,0,0,0,0
"Clinical failure as assessed in a time-to-event analysis favored tocilizumab over placebo (hazard ratio, 0.55; 95% CI, 0.33 to 0.93). ",0,0,0,0,0
"Death from any cause by day 28 occurred in 10.4% of the patients in the tocilizumab group and 8.6% of those in the placebo group (weighted difference, 2.0 percentage points; 95% CI, -﻿5.2 to 7.8).",0,0,0,0,0
"In the safety population, serious adverse events occurred in 38 of 250 patients (15.2%) in the tocilizumab group and 25 of 127 patients (19.7%) in the placebo group.",0,0,0,0,0
"Conclusions: In hospitalized patients with Covid-19 pneumonia who were not receiving mechanical ventilation, tocilizumab reduced the likelihood of progression to the composite outcome of mechanical ventilation or death, but it did not improve survival.",0,0,0,0,0
No new safety signals were identified.,0,0,0,0,0
COVID-19 mortality in patients on anticoagulants and antiplatelet agents,0,0,0,0,0
"Coagulopathy (Tang, et al 2020) and a prothrombotic diathesis with high D‐dimer and fibrinogen levels (Al‐Samkari, et al 2020) are associated with coronavirus disease 2019 (COVID‐19) caused by severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2).",0,0,0,0,0
Extensive thrombosis in small vessels and the microvasculature in lungs and extrapulmonary organs has been confirmed histologically (Zhang et al 2020). ,0,0,0,0,0
"Early studies showed that the venous thromboembolism (VTE) incidence in hospitalised COVID‐19 patients can be as high as 25% (Songping, et al 2020), and more recent studies have indicated this can be expanded to other macrovascular thrombotic complications, such as a higher than expected prevalence of pulmonary emboli in patients with COVID‐19 (Klok, et al 2020, Stoneham, et al).",0,0,0,0,0
Sialendoscopy increases saliva secretion and reduces xerostomia up to 60 weeks in Sjögren's syndrome patients: a randomized controlled study,1,0,0,0,0
Objective: To assess the effect of sialendoscopy of the major salivary glands on salivary flow and xerostomia in patients with Sjögren's syndrome (SS).,0,0,0,0,0
"Methods: Forty-five patients with SS were randomly assigned to a control group (no irrigation, control, n = 15), to irrigation of the major salivary glands with saline (saline, n = 15) or to irrigation with saline followed by corticosteroid application (triamcinolone acetonide in saline, saline/TA, n = 15).",1,0,0,0,0
"Unstimulated whole saliva flow (UWSF), chewing-stimulated whole saliva flow (SWSF), citric acid-stimulated parotid flow, Clinical Oral Dryness Score (CODS), Xerostomia Inventory (XI) and EULAR SS Patient Reported Index (ESSPRI) scores were obtained 1 week before (T0), and 1, 8, 16, 24, 36, 48 and 60 weeks after sialendoscopy.",0,0,0,0,0
Data were analysed using linear mixed models.,0,0,0,0,0
"Results: Irrespective of the irrigation protocol used, sialendoscopy resulted in an increased salivary flow during follow-up up to 60 weeks",0,0,0,0,0
"Significant between-group differences in the longitudinal course of outcomes were found for UWSF, SWSF, XI and ESSPRI scores (P = 0.028, P = 0.001, P = 0.03, P = 0.021, respectively)",0,0,0,0,0
"UWSF at 60 weeks was higher compared with T0 in the saline group (median: 0.14 vs median: 0.10, P = 0.02) and in the saline/TA group (median: 0.20, vs 0.13, P = 0.035).",0,0,0,0,0
"In the saline/TA group SWSF at 48 weeks was higher compared with T0 (median: 0.74 vs 0.38, P = 0.004).",0,0,0,0,0
"Increase in unstimulated salivary flow was also reflected in improved CODS, XI and ESSPRI scores compared with baseline.",0,0,0,0,0
Conclusion: Irrigation of the major salivary glands in patients with SS increases salivary flow and reduces xerostomia.,0,0,0,0,0
"Homeopathy for depression: a randomized, partially double-blind, placebo-controlled, four-armed study (DEP-HOM)",1,1,0,0,0
Background: The specific clinical benefit of the homeopathic consultation and of homeopathic remedies in patients with depression has not yet been investigated.,0,0,0,0,0
"Aims: To investigate the 1) specific effect of individualized homeopathic Q-potencies compared to placebo and 2) the effect of an extensive homeopathic case taking (case history I) compared to a shorter, rather conventional one (case history II) in the treatment of acute major depression (moderate episode) after six weeks.",0,0,0,0,0
"Methods: A randomized, partially double-blind, placebo-controlled, four-armed trial using a 2×2 factorial design with a six-week study duration per patient was performed.",1,1,0,1,0
"Results: A total of 44 from 228 planned patients were randomized (2∶1∶2∶1 randomization: 16 homeopathic Q-potencies/case history I, 7 placebo/case history I, 14 homeopathic Q-potencies/case history II, 7 placebo/case history II).",1,0,0,1,0
"Because of recruitment problems, the study was terminated prior to full recruitment, and was underpowered for the preplanned confirmatory hypothesis testing.",0,0,0,0,0
Exploratory data analyses showed heterogeneous and inconclusive results with large variance in the sample.,0,0,0,0,0
The mean difference for the Hamilton-D after 6 weeks was 2.0 (95%CI -1.2;5.2) for Q-potencies vs. placebo and -3.1 (-5.9;-0.2) for case history I vs. case history II. ,0,0,0,0,0
"Overall, no consistent or clinically relevant results across all outcomes between homeopathic Q-potencies versus placebo and homeopathic versus conventional case taking were observed.",0,0,0,0,0
The frequency of adverse events was comparable for all groups.,0,0,0,0,0
"Conclusions: Although our results are inconclusive, given that recruitment into this trial was very difficult and we had to terminate early, we cannot recommend undertaking a further trial addressing this question in a similar setting. Prof. Dr. Claudia Witt had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.",0,0,0,0,0
Homeopathy for attention-deficit/hyperactivity disorder: a pilot randomized-controlled trial,1,0,0,0,0
Objectives: The aim of this study was to carry out a preliminary trial evaluating the effectiveness of homeopathy in the treatment of attention-deficit/hyperactivity disorder (ADHD).,0,0,0,0,0
"Design: This work was a randomized, double-blind, placebo-controlled trial.",1,1,0,0,0
Settings/location: This study was conducted in a private homeopathic clinic in the Seattle metropolitan area.,0,0,0,0,0
Subjects: Subjects included children 6-12 years of age meeting Diagnostic and Statistical Manual of Mental Disorders 4th edition (DSM-IV) criteria for ADHD.,0,0,0,0,0
Interventions: Forty-three subjects were randomized to receive a homeopathic consultation and either an individualized homeopathic remedy or placebo.,1,0,0,0,0
Patients were seen by homeopathic physicians every 6 weeks for 18 weeks.,0,0,0,0,0
"Outcome measures: Outcome measures included the Conner's Global Index-Parent, Conner's Global Index- Teacher, Conner's Parent Rating Scale-Brief, Continuous Performance Test, and the Clinical Global Impression Scale.",0,0,0,0,0
Results: There were no statistically significant differences between homeopathic remedy and placebo groups on the primary or secondary outcome variables.,0,0,0,0,0
"However, there were statistically and clinically significant improvements in both groups on many of the outcome measures.",0,0,0,0,0
Conclusions: This pilot study provides no evidence to support a therapeutic effect of individually selected homeopathic remedies in children with ADHD.,0,0,0,0,0
A therapeutic effect of the homeopathic encounter is suggested and warrants further evaluation.,0,0,0,0,0
Future studies should be carried out over a longer period of time and should include a control group that does not receive the homeopathic consultation,0,0,0,0,0
Comparison to conventional stimulant medication for ADHD also should be considered.,0,0,0,0,0
"Adjunct prednisone therapy for patients with community-acquired pneumonia: a multicentre, double-blind, randomised, placebo-controlled trial",1,1,0,0,0
Background: Clinical trials yielded conflicting data about the benefit of adding systemic corticosteroids for treatment of community-acquired pneumonia.,0,0,0,0,0
We assessed whether short-term corticosteroid treatment reduces time to clinical stability in patients admitted to hospital for community-acquired pneumonia.,0,0,0,0,0
"Methods: In this double-blind, multicentre, randomised, placebo-controlled trial, we recruited patients aged 18 years or older with community-acquired pneumonia from seven tertiary care hospitals in Switzerland within 24 h of presentation.",1,1,0,0,0
Patients were randomly assigned (1:1 ratio) to receive either prednisone 50 mg daily for 7 days or placebo. ,0,0,0,0,0
The computer-generated randomisation was done with variable block sizes of four to six and stratified by study centre.,1,0,0,1,0
"The primary endpoint was time to clinical stability defined as time (days) until stable vital signs for at least 24 h, and analysed by intention to treat.",0,0,0,0,0
" This trial is registered with ClinicalTrials.gov, number NCT00973154.",0,0,0,0,0
"Findings: From Dec 1, 2009, to May 21, 2014, of 2911 patients assessed for eligibility, 785 patients were randomly assigned to either the prednisone group (n=392) or the placebo group (n=393).",1,0,0,0,0
"Median time to clinical stability was shorter in the prednisone group (3·0 days, IQR 2·5-3·4) than in the placebo group (4·4 days, 4·0-5·0; hazard ratio [HR] 1·33, 95% CI 1·15-1·50, p<0·0001).",0,0,0,0,0
Pneumonia-associated complications until day 30 did not differ between groups (11 [3%] in the prednisone group and 22 [6%] in the placebo group; odds ratio [OR] 0·49 [95% CI 0·23-1·02]; p=0·056).,0,0,0,0,0
"The prednisone group had a higher incidence of in-hospital hyperglycaemia needing insulin treatment (76 [19%] vs 43 [11%]; OR 1·96, 95% CI 1·31-2·93, p=0·0010). ",0,0,0,0,0
Other adverse events compatible with corticosteroid use were rare and similar in both groups.,0,0,0,0,0
Interpretation: Prednisone treatment for 7 days in patients with community-acquired pneumonia admitted to hospital shortens time to clinical stability without an increase in complications.,0,0,0,0,0
This finding is relevant from a patient perspective and an important determinant of hospital costs and efficiency.,0,0,0,0,0
Effect of corticosteroids on treatment failure among hospitalized patients with severe community-acquired pneumonia and high inflammatory response: a randomized clinical trial,1,0,0,0,0
"Importance: In patients with severe community-acquired pneumonia, treatment failure is associated with excessive inflammatory response and worse outcomes.",0,0,0,0,0
" Corticosteroids may modulate cytokine release in these patients, but the benefit of this adjunctive therapy remains controversial.",0,0,0,0,0
Objective: To assess the effect of corticosteroids in patients with severe community-acquired pneumonia and high associated inflammatory response.,0,0,0,0,0
"Design, setting, and participants: Multicenter, randomized, double-blind, placebo-controlled trial conducted in 3 Spanish teaching hospitals involving patients with both severe community-acquired pneumonia and a high inflammatory response, which was defined as a level of C-reactive protein greater than 150 mg/L at admission. ",1,1,0,0,0
Patients were recruited and followed up from June 2004 through February 2012.,0,0,0,0,0
Interventions: Patients were randomized to receive either an intravenous bolus of 0.5 mg/kg per 12 hours of methylprednisolone (n = 61) or placebo (n = 59) for 5 days started within 36 hours of hospital admission.,0,0,0,0,0
"Main outcomes and measures: The primary outcome was treatment failure (composite outcome of early treatment failure defined as [1] clinical deterioration indicated by development of shock, [2] need for invasive mechanical ventilation not present at baseline, or [3] death within 72 hours of treatment; or composite outcome of late treatment failure defined as [1] radiographic progression, [2] persistence of severe respiratory failure, [3] development of shock, [4] need for invasive mechanical ventilation not present at baseline, or [5] death between 72 hours and 120 hours after treatment initiation; or both early and late treatment failure)",0,0,0,0,0
In-hospital mortality was a secondary outcome and adverse events were assessed.,0,0,0,0,0
"Results: There was less treatment failure among patients from the methylprednisolone group (8 patients [13%]) compared with the placebo group (18 patients [31%]) (P = .02), with a difference between groups of 18% (95% CI, 3% to 32%)",0,0,0,0,0
"Corticosteroid treatment reduced the risk of treatment failure (odds ratio, 0.34 [95% CI, 0.14 to 0.87]; P = .02).",0,0,0,0,0
" In-hospital mortality did not differ between the 2 groups (6 patients [10%] in the methylprednisolone group vs 9 patients [15%] in the placebo group; P = .37); the difference between groups was 5% (95% CI, -6% to 17%). Hyperglycemia occurred in 11 patients (18%) in the methylprednisolone group and in 7 patients (12%) in the placebo group (P = .34).",0,0,0,0,0
"Conclusions and relevance: Among patients with severe community-acquired pneumonia and high initial inflammatory response, the acute use of methylprednisolone compared with placebo decreased treatment failure. If replicated, these findings would support the use of corticosteroids as adjunctive treatment in this clinical population.",0,0,0,0,0
"The ASTIS trial was an investigator-initiated, randomized, open-label, parallel-group trial conducted in 10 countries at 29 centers with access to a European Group for Blood and Marrow Transplantation–registered transplant facility.",1,0,0,0,0
"15 Patients were eligible if they were between 18 and 65 years of age; had diffuse cutaneous systemic sclerosis according to American Rheumatism Association criteria,16 with maximum disease duration of 4 years; minimum modified Rodnan skin score (mRSS) of 15 (range, 0-51, with higher scores indicating more severe skin thickening); and involvement of heart, lungs, or kidneys (eAppendix in the Supplement). ",0,0,0,0,0
Prior treatment with cyclophosphamide was allowed up to a cumulative dose of 5 g intravenously or up to 2 mg/kg body weight orally for 3 months.,0,0,0,0,0
Patients with severe major organ involvement including severe pulmonary arterial hypertension (PAH) (mean pulmonary artery pressure >50 mm Hg) or serious comorbidities were excluded. ,0,0,0,0,0
"The protocol was amended in 2004 to allow inclusion of patients with disease duration of 2 years or less and no major organ dysfunction as defined above, provided they had an mRSS of at least 20 and an erythrocyte sedimentation rate greater than 25 mm in the first hour and/or hemoglobin less than 11 g/dL not explained by causes other than active scleroderma. ",0,0,0,0,0
"The protocol was further amended in 2008 to make it compliant with the European Union Directive for Clinical Trials, to change the power calculation because of a lower than expected accrual and event rate, and to include guidance on monitoring and treatment of Epstein-Barr virus (EBV) reactivation after HSCT.",0,0,0,0,0
"After registration, patients were randomly assigned in a 1:1 ratio by blocked randomization to receive HSCT or 12 intravenous pulses of cyclophosphamide (Figure 1).",1,0,0,1,0
"Block randomization was performed centrally by telephone at the study administration office according to a computer-generated randomization program for each site, with random block sizes (2, 4, 6).",1,0,0,1,0
"Treatment was allocated within blocks according to an optimum assignment procedure (minimization) to balance the investigational and standard treatment groups for age (≤40 years, >40 years) and disease duration (<2 years, ≥2 years) but included a 25% chance to be assigned to the nonoptimal group.",0,0,0,0,0
Patients and assessors were not blinded,0,0,0,0,0
"Ten patients with SSc were randomized to ACHIM (n = 5) or placebo (n = 5) in a double-blind, placebo-controlled 16-week pilot. ",1,1,0,0,0
"All patients had mild to severe upper and lower GI symptoms including diarrhea, distention/bloating and/or fecal incontinence at baseline.",0,0,0,0,0
Gastroduodenoscopy transfer of ACHIM or placebo was performed at weeks 0 and 2.,0,0,0,0,0
Primary endpoints were safety and clinical efficacy on GI symptoms assessed at weeks 4 and 16. ,0,0,0,0,0
"Secondary endpoints included changes in relative abundance of total, immunoglobulin (Ig) A- and IgM-coated fecal bacteria measured by 16s rRNA sequencing.",0,0,0,0,0
Eligible participants were randomly assigned to treatment. ,1,0,0,0,0
An unblinded staff member (TG) who was not otherwise involved in the clinical aspects of the study generated the random sequence for treatment assignment. ,1,0,0,1,0
All patients and care providers responsible for assessing patients during the study and outcomes were blinded. ,0,1,0,0,0
"Active treatment and placebo were packaged, and handled so that participants and study staff were not able to distinguish between treatments. ",0,0,0,0,1
"Participants, study staff performing safety and efficacy assessments and analyzing safety and other trial data were blinded to group assignment until the database was locked.",0,1,0,0,0
"The study was registered at clinicaltrials.gov (NCT03444220), one month after study start while still all participants and staff was blinded. ",0,1,0,0,0
"This was a double-blind, randomised, placebo-controlled, pilot study",1,1,0,0,0
"This double-blind, placebo-controlled trial conducted at 41 centres in Europe and North America randomised 188 patients with SSc with at least 1 active DU ('cardinal ulcer') to bosentan 62.5 mg twice daily for 4 weeks and 125 mg twice daily thereafter for 20 weeks (n=98) or matching placebo (n=90; total 24 weeks). ",0,1,0,0,0
"After screening, patients were randomised to bosentan or placebo (1:1 ratio) by sequential allocation of randomisation numbers distributed to each centre in blocks of four. ",1,0,0,1,0
"This double-blind, randomised, parallel-group, placebo-controlled study consisted of a ≤2-week screening period, a 24-week treatment period and an 8-week post-treatment follow-up period. ",1,1,0,0,0
"In this randomised, placebo-controlled trial, bosentan treatment was associated with a 30% reduction in the number of new DUs over the 24-week treatment period but did not result in a treatment effect on healing of the cardinal ulcer.",1,0,0,0,0
Treatment-emergent hypertension and efficacy in the phase 3 Study of (E7080) lenvatinib in differentiated cancer of the thyroid (SELECT),0,0,0,0,0
Background: Hypertension (HTN) is an established class effect of vascular endothelial growth factor receptor (VEGFR) inhibition.,0,0,0,0,0
"In the phase 3 Study of (E7080) Lenvatinib in Differentiated Cancer of the Thyroid (SELECT) trial, HTN was the most frequent adverse event of lenvatinib, an inhibitor of VEGFR1, VEGFR2, VEGFR3, fibroblast growth factor receptor 1 (FGFR1), FGFR2, FGFR3, FGFR4, platelet-derived growth factor receptor α (PDGFRα), ret proto-oncogene (RET), and stem cell factor receptor (KIT).",0,0,0,0,0
This exploratory analysis examined treatment-emergent hypertension (TE-HTN) and its relation with lenvatinib efficacy and safety in SELECT.,0,0,0,0,0
"Methods: In the multicenter, double-blind SELECT trial, 392 patients with progressive radioiodine-refractory differentiated thyroid cancer (RR-DTC) were randomized 2:1 to lenvatinib (24 mg/d on a 28-day cycle) or placebo.",1,1,0,1,0
Survival endpoints were assessed with Kaplan-Meier estimates and log-rank tests.,0,0,0,0,0
The influence of TE-HTN on progression-free survival (PFS) and overall survival (OS) was analyzed with univariate and multivariate Cox proportional hazards models.,0,0,0,0,0
"Results: Overall, 73% of lenvatinib-treated patients and 15% of placebo-treated patients experienced TE-HTN.",0,0,0,0,0
"The median PFS for lenvatinib-treated patients with (n = 190) and without TE-HTN (n = 71) was 18.8 and 12.9 months, respectively (hazard ratio [HR], 0.59; 95% confidence interval [CI], 0.39-0.88; P = .0085).",0,0,0,0,0
"For lenvatinib-treated patients, the objective response rate was 69% with TE-HTN and 56% without TE-HTN (odds ratio, 1.72; 95% CI, 0.98-3.01).",0,0,0,0,0
"The median change in tumor size for patients with and without TE-HTN was -45% and -40%, respectively (P = .2).",0,0,0,0,0
"The median OS was not reached for patients with TE-HTN; for those without TE-HTN, it was 21.7 months (HR, 0.43; 95% CI, 0.27-0.69; P = .0003).",0,0,0,0,0
"Conclusions: Although HTN is a clinically significant adverse event that warrants monitoring and management, TE-HTN was significantly correlated with improved outcomes in patients with RR-DTC, indicating that HTN may be predictive for lenvatinib efficacy in this population. Cancer 2018;124:2365-72. © 2018 American Cancer Society.",0,0,0,0,0
"Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial",1,1,0,0,0
"Denosumab is a fully human monoclonal antibody that inhibits bone resorption by neutralizing RANKL, a key mediator of osteoclast formation, function, and survival. ",0,0,0,0,0
"This phase 3, multicenter, doubleblind study compared the efficacy and safety of denosumab with alendronate in postmenopausal women with low bone mass.",0,1,0,0,0
One thousand one hundred eighty-nine postmenopausal women with a T-score <or= -2.0 at the lumbar spine or total hip were randomized 1:1 to receive subcutaneous denosumab injections (60 mg every 6 mo [Q6M]) plus oral placebo weekly (n = 594) or oral alendronate weekly (70 mg) plus subcutaneous placebo injections Q6M (n = 595). ,1,0,0,1,0
"Changes in BMD were assessed at the total hip, femoral neck, trochanter, lumbar spine, and one-third radius at 6 and 12 mo and in bone turnover markers at months 1, 3, 6, 9, and 12. ",0,0,0,0,0
Safety was evaluated by monitoring adverse events and laboratory values.,0,0,0,0,0
"At the total hip, denosumab significantly increased BMD compared with alendronate at month 12 (3.5% versus 2.6%; p < 0.0001).",0,0,0,0,0
"Furthermore, significantly greater increases in BMD were observed with denosumab treatment at all measured skeletal sites (12-mo treatment difference: 0.6%, femoral neck; 1.0%, trochanter; 1.1%, lumbar spine; 0.6%, one-third radius; p <or= 0.0002 all sites).",0,0,0,0,0
Denosumab treatment led to significantly greater reduction of bone turnover markers compared with alendronate therapy.,0,0,0,0,0
Adverse events and laboratory values were similar for denosumab- and alendronate-treated subjects.,0,0,0,0,0
Denosumab showed significantly larger gains in BMD and greater reduction in bone turnover markers compared with alendronate.,0,0,0,0,0
The overall safety profile was similar for both treatments.,0,0,0,0,0
"Success and Behavior During Atraumatic Restorative Treatment, the Hall Technique, and the Stainless Steel Crown Technique for Primary Molar Teeth",0,0,0,0,0
"Purposes: The purposes of this prospective trial were to: (1) compare the clinical and radiographic outcomes of three restorative methods -modified atraumatic restorative treatment (mART), the Hall technique (HT), and stainless steel crown (SSC)-in primary molars with multi-surface carious lesions; and (2) assess child behavior throughout these treatments.",0,0,0,0,0
"Methods: In this randomized controlled trial (RCT), 123 primary molars in four- to nine-year-old children were randomly divided into treatment groups (HT, mART, and SSC).",1,0,0,0,0
"Variables, including signs of failure, treatment time, child's discomfort, child's behavior, and canine overbite relationship in HT, were recorded immediately after the treatment and at six- and 12-month recalls.",0,0,0,0,0
 Results: Failures occurred most significantly for mART at all recalls (P=0.001). ,0,0,0,0,0
The treatment time was significantly higher in SSC.,0,0,0,0,0
There was no significant difference in the child-assessment of discomfort (P=0.814). ,0,0,0,0,0
"The child's behavior, as evaluated by the dentist, however, was significantly better for the SSC group.",0,0,0,0,0
Alterations to the canine overbite relationship of HT decreased significantly during recalls (P<0.001),0,0,0,0,0
Conclusions: The high success and shorter treatment time of the Hall technique support its consideration as an alternative to the conventional technique for the treatment of carious primary teeth with multisurface lesions. ,0,0,0,0,0
The results for modified atraumatic restorative treatment were not as satisfying.,0,0,0,0,0
A randomized controlled trial of home bleaching of tetracycline-stained teeth,1,0,0,0,0
Objectives: To investigate the effectiveness of two home bleaching modalities on whitening of tetracycline-stained teeth (TST).,0,0,0,0,0
Methods: A randomized controlled trial on the bleaching effect of 15% carbamide peroxide gel loaded in tray and 6.5% hydrogen peroxide strip in subjects with TST was performed. ,1,0,0,0,0
"Eligible subjects were judged independently by two assessors, and randomly assigned into the tray or the strip group.",1,0,0,1,0
"Lightness (L*), redness (a*) and yellowness (b*) were measured with colorimeter at baseline, one, two and three months",0,0,0,0,0
Any adverse reaction associated with bleaching were also recorded.,0,0,0,0,0
Overall colour changes (ΔE) were analysed by one-sample and independent t-test/Wilcoxon test at significance level α=0.05.,0,0,0,0,0
Result: Twelve and fourteen participants were allocated to the tray and the strip group respectively.,0,0,0,0,0
Both groups experienced noticeable and significant L*a*b* improvement at the end of the trial in comparison to the baseline (p<0.05).,0,0,0,0,0
Significant improvement was observed in the first month for the tray group (p<0.05) and in the first two months for the strip group (p<0.05). ,0,0,0,0,0
"While greater lightness improvement was observed in the tray group over the strip group in the first month (p=0.02), the reverse was noticed in the second month (p=0.01). ",0,0,0,0,0
There was no difference between two groups at the end of this trial (p<0.05) and no significant adverse reactions were observed.,0,0,0,0,0
"Conclusion: Over a three-month period, 6.0% hydrogen peroxide strip performed equally well as the 15% carbamide peroxide tray delivery system in TST.",0,0,0,0,0
Clinical significance: Home bleaching systems produce noticeable tooth whitening effect in subjects with tetracycline-stained teeth.,0,0,0,0,0
Six months versus two years of oral anticoagulation after a first episode of unprovoked deep-vein thrombosis.,0,0,0,0,0
The PADIS-DVT randomized clinical trial,1,0,0,0,0
The optimal duration of anticoagulation after a first episode of unprovoked deep-vein thrombosis is uncertain.,0,0,0,0,0
"We aimed to assess the benefits and risks of an additional 18 months of treatment with warfarin versus placebo, after an initial 6 months of anticoagulation for a first unprovoked proximal deep-vein thrombosis. ",0,0,0,0,0
"We conducted a multicenter, randomized, double-blind, controlled trial comparing an additional 18 months of warfarin with placebo in patients with a unprovoked proximal deep-vein thrombosis initially treated for 6 months (treatment period: 18 months; follow up after treatment period: 24 months). ",1,1,0,0,0
The primary outcome was the composite of recurrent venous thromboembolism or major bleeding at 18 months.,0,0,0,0,0
"Secondary outcomes were the composite at 42 months, as well as each component of the composite, and death unrelated to pulmonary embolism or major bleeding, at 18 and 42 months.",0,0,0,0,0
All outcomes were centrally adjudicated. ,0,0,0,0,0
"A total of 104 patients, enrolled between July 2007 and October 2013 were analyzed on an intention-to-treat basis; no patient was lost to follow-up.",0,0,1,0,0
"During the 18-month treatment period, the primary outcome occurred in none of the 50 patients in the warfarin group and in 16 out of 54 patients (cumulative risk, 29.6%) in the placebo group (hazard ratio, 0.03; 95% confidence interval: 0.01 to 0.09; P<0.001). ",0,0,0,0,0
"During the entire 42-month study period, the composite outcome occurred in 14 patients (cumulative risk, 36.8%) in the warfarin group and 17 patients (cumulative risk, 31.5%) in the placebo group (hazard ratio, 0.72; 95% confidence interval: 0.35-1.46).",0,0,0,0,0
"In conclusion, after a first unprovoked proximal deep-vein thrombosis initially treated for 6 months, an additional 18 months of warfarin therapy reduced the composite of recurrent venous thrombosis and major bleeding compared to placebo. ",0,0,0,0,0
"However, this benefit was not maintained after stopping anticoagulation.",0,0,0,0,0
Effects of aerobic exercise on cognition and hippocampal volume in Alzheimer's disease: study protocol of a randomized controlled trial (The FIT-AD trial),1,0,0,0,0
"Background: Alzheimer's disease, a global public health issue, accounts for 60 to 80% of all dementias.",0,0,0,0,0
" Alzheimer's disease primarily causes cognitive impairment and drugs have only modest short-term effects, highlighting a pressing need to develop effective interventions.",0,0,0,0,0
Aerobic exercise holds promise for treating cognitive impairment in Alzheimer's disease through biologically sound mechanisms.,0,0,0,0,0
"Nonetheless, aerobic exercise studies in Alzheimer's disease are limited with mixed findings.",0,0,0,0,0
"Methods/design: This pilot randomized controlled trial will investigate the effects of a 6-month, individualized, moderate-intensity cycling intervention (20 to 50 minutes per session, 3 times a week) on cognition and hippocampal volume in community-dwelling older adults with mild-to-moderate Alzheimer's disease.",1,0,0,0,0
The specific aims are to: 1) determine the immediate effect of the cycling intervention on cognition in Alzheimer's disease; 2) examine if the cycling intervention slows cognitive decline in Alzheimer's disease from baseline to 12 months; and 3) assess the effect of aerobic exercise on hippocampal volume over 12 months. ,0,0,0,0,0
Ninety subjects will be randomized on a 2:1 allocation ratio to cycling or attention control (low-intensity stretching) and followed for another 6 months.,1,0,0,1,0
Allocations will be concealed to all investigators and outcome assessors will be blinded to group assignments and previous data.,0,1,0,0,0
"Cognition will be measured by the Alzheimer's disease Assessment Scale-Cognition at baseline before randomization and at 3, 6, 9, and 12 months.",1,0,0,0,0
Hippocampal volume will be measured by magnetic resonance imaging at baseline and 6 and 12 months.,0,0,0,0,0
The sample size of 90 will give 80% power to detect a 2.5-point difference in within-group changes in the Alzheimer's disease Assessment Scale-Cognition at 6 months for the cycling group.,0,0,0,0,0
Discussion: Findings from this study will address the critical gap of exercise efficacy in Alzheimer's disease and use of magnetic resonance imaging as an outcome measure in clinical trials.,0,0,0,0,0
This study will provide a potential treatment that may increase physical function and quality of life and curb the prohibitive costs for the growing dementia population.,0,0,0,0,0
Home based training for dexterity in Parkinson's disease: A randomized controlled trial,1,0,0,0,0
Background: Patients with Parkinson's disease exhibit disturbed manual dexterity.,0,0,0,0,0
"This impairment leads to difficulties in activities of daily living, such as buttoning a shirt or hand-writing.",0,0,0,0,0
"The aim of the present study was to investigate the effectiveness of a home-based dexterity program on fine motor skills in a single-blinded, randomized controlled trial, in patients with Parkinson's disease.",1,0,0,0,0
"Methods: One hundred and three patients with Parkinson's disease (aged between 48 and 80 years, Hoehn & Yahr stage I-IV) were randomized to either a home-based dexterity program (HOMEDEXT) or Thera-band program.",1,0,0,0,0
"All patients trained over a period of 4 weeks, 5 times/week, 30 min for each session.",0,0,0,0,0
" A baseline, post-intervention, and follow-up assessment (12 weeks later, time period without intervention) were done. ",0,0,0,0,0
 The primary outcome measure was dexterity as measured with the Nine Hole peg test (9-HPT).,0,0,0,0,0
"Secondary outcome measures included strength, motor parkinsonian symptoms, dexterity-related activities of daily living (ADL) and Health-related Quality of Life (HrQoL).",0,0,0,0,0
Results: There was a significant difference in favor of the HOMEDEXT group as compared to the Thera-band group on the primary outcome 9-HPT (p = 0.006) and dexterity-related ADL (p = 0.02) at post intervention.,0,0,0,0,0
"No significant differences were found for the other outcomes, nor at follow-up.",0,0,0,0,0
"Conclusion: This is the first randomized controlled trial showing that an intensive, task specific home-based dexterity program significantly improved fine motor skills in Parkinson's disease. ",1,0,0,0,0
The effect generalized to dexterity-related ADL functions,0,0,0,0,0
" As these improvements did not sustain, the finding suggest that continuous training is required to maintain the benefit.",0,0,0,0,0
"Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial",1,0,0,0,0
"Background: Systemic lupus erythematosus is a heterogeneous autoimmune disease that is associated with B-cell hyperactivity, autoantibodies, and increased concentrations of B-lymphocyte stimulator (BLyS). ",0,0,0,0,0
The efficacy and safety of the fully human monoclonal antibody belimumab (BLyS-specific inhibitor) was assessed in patients with active systemic lupus erythematosus.,0,0,0,0,0
"Methods: Patients (aged ≥18 years) who were seropositive with scores of at least 6 on the Safety of Estrogens in Lupus Erythematosus National Assessment-Systemic Lupus Erythematosus Disease Activity Index (SELENA-SLEDAI) were enrolled in a multicentre phase 3 study, which was done in Latin America, Asia-Pacific, and eastern Europe.",0,0,0,0,0
"Patients were randomly assigned by use of a central interactive voice response system in a 1:1:1 ratio to belimumab 1 mg/kg or 10 mg/kg, or placebo by intravenous infusion in 1 h on days 0, 14, and 28, and then every 28 days until 48 weeks, with standard of care. ",1,0,0,1,0
"Patients, investigators, study coordinators, and sponsors were masked to treatment assignment.",0,0,0,0,0
Primary efficacy endpoint was improvement in the Systemic Lupus Erythematosus Responder Index (SRI) at week 52 (reduction ≥4 points in SELENA-SLEDAI score; no new British Isles Lupus Assessment Group [BILAG] A organ domain score and no more than 1 new B organ domain score; and no worsening [<0·3 increase] in Physician's Global Assessment [PGA] score) versus baseline.,0,0,0,0,0
"Method of analysis was by modified intention to treat. This trial is registered with ClinicalTrials.gov, number",0,0,0,0,0
"Findings: 867 patients were randomly assigned to belimumab 1 mg/kg (n=289) or 10 mg/kg (n=290), or placebo (n=288).",1,0,0,0,0
"Results of a multicenter, open-label, randomized controlled trial of corticosteroid and cyclophosphamide-based induction therapy",1,0,0,0,0
Randomization used a 1:1 ratio computer-generated list and was performed centrally with sealed opaque envelopes.,1,0,0,1,0
"A multicenter, open-label, randomized controlled trial comprising patients ≥65 years old and newly diagnosed as having SNV was conducted.",1,0,0,0,0
"Patients were studied in a randomized, double-blind, cross-over, placebo controlled study lasting 12 weeks.",1,1,0,0,0
Participants were randomised into wax bath versus no wax bath groups.,1,0,0,0,0
A 6-month randomized controlled trial was conducted on SSc patients by comparing a home-based minimally supervised exercise program (exercise on a stationary cycle and strengthening of upper limbs; stretching of the hands) with usual care,1,0,0,0,0
"Twenty-two were randomly assigned to the intervention group (IG, mean age 63.60 ± 10.40 years) and 22 to the control group (CG, 61.80 ± 14.40 years)",1,0,0,0,0
Blinding was maintained throughout the study.,0,1,0,0,0
The allocation key was kept by the compounding pharmacy until completion of the study.,0,0,0,0,1
Randomization was performed centrally according to study identification (ID) number by personnel not involved with recruitment or analysis.,1,0,0,1,0
Stratification by site was performed and each site’s randomization was performed in block sizes of 6.,1,0,0,1,0
Enrolled patients were randomized (1:1:1) to receive rapamycin (1% or 0.1%) or vehicle-only using a computerized random number generator.,1,0,0,1,0
"Patients were randomized (1:1:1) to topical formulation containing 0.3 g per 30 g (1%) rapamycin, 0.03 g per 30 g (0.1%) rapamycin, or vehicle alone",1,0,0,1,0
"This prospective, multicenter, randomized, double-blind, vehicle-controlled trial with 6 monthly clinic visits enrolled 179 patients with TSC-related facial angiofibromas not treated within 6 months from May 2012 to March 2014 in 9 clinical sites in the United States and 1 in Australia.",1,1,0,0,0
A total of 267 subjects agreed to participate in the study and were randomized to either group,1,0,0,0,0
"In addition, block randomization of patients occurred in groups of 50.",1,0,0,1,0
"Although the assignment to either group was random, to ensure that the proportion of patients with more or fewer depressive symptoms was approximately the same in both groups, after every 50 patients were recruited, the assignment of patients to each group up to that point was cross-tabulated with respect to PHQ-8 scores. ",1,0,0,1,0
Stratification based on the PHQ-8 score was pursued because we hypothesized that participants who reported being depressed may have poor coping and self-management skills. ,0,0,0,1,0
"Randomization was performed using a 1:1 ratio and via computer-generated block randomization, with stratification based on the PHQ-8 score (respectively, <10, ≥10) to ensure that subjects with depressive symptoms were equally distributed in the two groups",1,0,0,1,0
Participants who completed the consent were randomized to either an intervention or control group,1,0,0,0,0
"Of the 267 participants who completed baseline questionnaires and were randomized to the intervention (internet: www.selfmanagescleroderma.com) or control (book) group, 123 participants (93%) in the internet group and 124 participants (94%) in the control group completed the 16-week randomized controlled trial (RCT).",1,0,0,0,0
"We conducted a 16-week randomized, controlled trial",1,0,0,0,0
This is the first randomised control trial to study the efficacy of rituximab as first-line treatment in CTD-associated ILD,1,0,0,0,0
"A total of 116 individuals will be randomised 1:1 to each of the two treatment arms, with stratification based on underlying CTD, and will be followed for a total of 48 weeks from first dose",1,0,0,1,0
"RECITAL is a UK, multicentre, prospective, randomised, double-blind, double-dummy, controlled trial funded by the Efficacy and Mechanism Evaluation Programme of the Medical Research Council and National Institute for Health Research",1,1,0,0,0
Non-randomised studies of haemopoietic stem-cell transplantation (HSCT) in systemic sclerosis have shown improvements in lung function and skin flexibility but high treatment-related mortality.,0,0,0,0,0
Sialendoscopy of Salivary Glands Affected by Sjögren Syndrome: A Randomized Controlled Pilot Study,1,0,0,0,0
"A double-blind, randomized control study was conducted in 39 subjects of 153 pSS subjects for 2 years",1,1,0,0,0
Twenty patients diagnosed with SS were randomly assigned to a nonintervention control group or a sialendoscopy group,1,0,0,0,0
Effect of Hydroxychloroquine Treatment on Dry Eyes in Subjects with Primary Sjögren's Syndrome: a Double-Blind Randomized Control Study,1,1,0,0,0
Forty-nine patients with SS were randomly assigned to a control group (n=15) and two intervention groups: irrigation of the major glands with saline (n=16) or with saline followed by triamcinolone acetonide (TA) in saline (n=18),1,0,0,0,0
"A double-blind, cross-over, study of oral N-acetylcysteine in Sjögren's syndrome",0,1,0,0,0
This randomized controlled trial was conducted at the Department of Ophthalmology at Seoul National University Hospital from May 2011 through August 2013,1,0,0,0,0
"Twenty-six patients with primary or secondary Sjögren's syndrome were treated in a double-blind, cross-over trial for a four week period with oral N-Acetylcysteine and placebo",0,1,0,0,0
"The SARS-CoV-2 Ivermectin Navarra-ISGlobal Trial (SAINT) to Evaluate the Potential of Ivermectin to Reduce COVID-19 Transmission in low risk, non-severe COVID-19 patients in the first 48 hours after symptoms onset: A structured summary of a study protocol for a randomized control pilot trial",1,0,0,0,0
Fifty-six outpatients with primary and 4 patients with secondary Sjögren's syndrome were assigned randomly into treatment groups of either IFN-alpha or sucralfate (control),1,0,0,0,0
"This randomised, double-blind, placebo-controlled, phase 2 trial of the Ad5-vectored COVID-19 vaccine was done in a single centre in Wuhan, China",1,1,0,0,0
Investigators allocated participants at a ratio of 2:1:1 to receive a single injection intramuscularly in the arm,1,0,0,1,0
"A study identification code with the format ""SAINT-##"" (##: from 01 to 24) will be generated using a sequence of random numbers so that the randomization number does not match the subject identifier",1,0,0,1,0
The clinical trial team and the patients will be blinded,0,1,0,0,0
"A double-blind, randomized control study was conducted in 39 pSS subjects from May 2011 through August 2013",1,1,0,0,0
A separate set of 24 envelopes for emergency unblinding will be kept in the study file,0,0,0,0,1
"The placebo will not be visibly identical, but it will be administered by staff not involved in the clinical care or participant follow up",0,0,0,0,1
The randomisation list (block size 4) was generated by an independent statistician,1,0,0,1,0
"Participants, investigators, and staff undertaking laboratory analyses were masked to group allocation",0,0,0,0,1
A single-blinded controlled trial was conducted to test the efficacy of low-dose oral human interferon-alpha (IFN-alpha) to improve salivary function in patients with Sjögren's syndrome.,0,1,0,0,0
The experimental vaccines and placebos had identical packaging with a randomisation number on each vial as the only identifiers,1,0,0,0,1
"Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial",1,1,0,0,0
The vaccines of 1 × 1011 and 5 × 1010 viral particles and placebo were randomised at a 2:1:1 ratio,1,0,0,1,0
"Participants will be randomized to receive a single dose of 400 μg/kg ivermectin or placebo, and the number of patients in the treatment and placebo groups will be the same (1:1 ratio)",1,0,0,1,0
"Eligible participants were sequentially assigned a randomisation number, according to a blocked randomisation list (block size 4) generated by an independent statistician using SAS software (version 9.4)",1,0,0,1,0
"Participants, investigators, and staff undertaking laboratory analyses were masked to group allocation",0,0,0,0,1
Eligible patients will be allocated in a 1:1 ratio using a randomization list generated by the trial statistician using blocks of four to ensure balance between the groups,1,0,0,1,0
Evaluating the efficacy and safety of human anti-SARS-CoV-2 convalescent plasma in severely ill adults with COVID-19: A structured summary of a study protocol for a randomized controlled trial,1,0,0,0,0
"SAINT is a single centre, double-blind, randomized, placebo-controlled, superiority trial with two parallel arms",1,1,0,0,0
The study participants and the clinicians who will evaluate post-treatment outcomes will be blinded to group assignment,0,1,0,0,1
The blood bank and the clinical research team will not be blinded to group assignment,0,0,0,0,1
Study participants will be randomized in a 2:1 ratio to receive anti-SARS-CoV-2 plasma versus control plasma using a web-based randomization platform,1,0,0,1,0
A Cluster-Randomized Trial of Hydroxychloroquine for Prevention of Covid-19,1,0,0,0,0
"This is a prospective, single-center, phase 2, randomized, controlled trial that is blinded to participants and clinical outcome assessor",1,1,0,0,0
"We conducted an open-label, cluster-randomized trial involving asymptomatic contacts of patients with polymerase-chain-reaction (PCR)-confirmed Covid-19 in Catalonia, Spain",1,0,0,0,0
"We randomly assigned clusters of contacts to the hydroxychloroquine group (which received the drug at a dose of 800 mg once, followed by 400 mg daily for 6 days) or to the usual-care group (which received no specific therapy)",1,0,0,0,0
Included participants will be hospitalized at the time of randomization and plasma infusion,1,0,0,0,0
A total of 1116 contacts were randomly assigned to receive hydroxychloroquine and 1198 to receive usual care,1,0,0,0,0
Treatment assignments will be generated using randomly permuted blocks of different sizes to minimize imbalance while also minimizing predictability.,1,0,0,1,0
"The randomisation code will be generated by the CTU (Clinical Trials Unit, ZKS Freiburg) using the following procedure to ensure that treatment assignment is unbiased and concealed from patients and investigator staff",1,0,0,1,0
Single-blinded controlled trial of low-dose oral IFN-alpha for the treatment of xerostomia in patients with Sjögren's syndrome,0,1,0,0,0
Blinding of the participants and the examiner was maintained until all clinical data were collected at 24-month,0,1,0,0,0
Concealment of participant allocation was kept by a clinical staff who was not involved in the trial,0,0,0,0,1
"To ensure comparability of the characteristics of the subjects in the intervention and control groups, a stratified block randomization method with a block size of four was applied so that a similar number of pSS and sSS subjects were allocated to each group",1,0,0,1,0
Dental records of 15 SS patients were randomly selected from those who had participated in previous consecutive studies revealed a mean caries increment of 3.5 surfaces (SD = 2.8) over 24 months,1,0,0,1,0
"Randomized, double-blind, placebo-controlled clinical trial design which lasted for 24 months was employed",1,1,0,0,0
Results of this randomized clinical trial did not provide clear evidence to support or refute that quarterly applications of fluoride varnish can prevent development of dental caries in people with Sjögren's syndrome.,1,0,0,0,0
"In this 24-month randomized, double-blind, placebo-controlled clinical trial, SS patients were randomly assigned to receive either fluoride varnish or placebo gel quarterly",1,1,0,0,0
"A randomized, double-blind, placebo-controlled clinical trial of fluoride varnish in preventing dental caries of Sjögren's syndrome patients",1,1,0,0,0
"Forty-five sedentary women fulfilling the American European Consensus Criteria for pSS were randomized to a training group (TG, n = 23) or control group (CG, n = 22).",1,0,0,0,0
"Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia (APEKS-NP): a randomised, double-blind, phase 3, non-inferiority trial",1,1,0,0,0
Background: Nosocomial pneumonia due to multidrug-resistant Gram-negative pathogens poses an increasing challenge,0,0,0,0,0
"We compared the efficacy and safety of cefiderocol versus high-dose, extended-infusion meropenem for adults with nosocomial pneumonia.",0,0,0,0,0
"Methods: We did a randomised, double-blind, parallel-group, phase 3, non-inferiority trial in 76 centres in 17 countries in Asia, Europe, and the USA (APEKS-NP). ",1,1,0,0,0
"We enrolled adults aged 18 years and older with hospital-acquired, ventilator-associated, or health-care-associated Gram-negative pneumonia, and randomly assigned them (1:1 by interactive response technology) to 3-h intravenous infusions of either cefiderocol 2 g or meropenem 2 g every 8 h for 7-14 days.",1,0,0,1,0
All patients also received open-label intravenous linezolid (600 mg every 12 h) for at least 5 days. ,0,0,0,0,0
An unmasked pharmacist prepared the assigned treatments; investigators and patients were masked to treatment assignment.,0,0,0,0,0
"Only the unmasked pharmacist was aware of the study drug assignment for the infusion bags, which were administered in generic infusion bags labelled with patient and study site identification numbers.",0,0,0,0,0
Participants were stratified at randomisation by infection type and Acute Physiology and Chronic Health Evaluation II (APACHE II) score (≤15 and ≥16). ,1,0,0,0,0
"The primary endpoint was all-cause mortality at day 14 in the modified intention-to-treat (ITT) population (ie, all patients receiving at least one dose of study drug, excluding patients with Gram-positive monomicrobial infections).",0,0,0,0,0
The analysis was done for all patients with known vital status.,0,0,0,0,0
Non-inferiority was concluded if the upper bound of the 95% CI for the treatment difference between cefiderocol and meropenem groups was less than 12·5%. ,0,0,0,0,0
"Safety was investigated to the end of the study in the safety population, which included all patients who received at least one dose of study drug.",0,0,0,0,0
"Findings: Between Oct 23, 2017, and April 14, 2019, we randomly assigned 148 participants to cefiderocol and 152 to meropenem.",1,0,0,0,0
"Of 292 patients in the modified ITT population, 251 (86%) had a qualifying baseline Gram-negative pathogen, including Klebsiella pneumoniae (92 [32%]), Pseudomonas aeruginosa (48 [16%]), Acinetobacter baumannii (47 [16%]), and Escherichia coli (41 [14%]).",0,0,0,0,0
"142 (49%) patients had an APACHE II score of 16 or more, 175 (60%) were mechanically ventilated, and 199 (68%) were in intensive care units at the time of randomisation",1,0,0,0,0
"All-cause mortality at day 14 was 12·4% with cefiderocol (18 patients of 145) and 11·6% with meropenem (17 patients of 146; adjusted treatment difference 0·8%, 95% CI -6·6 to 8·2; p=0·002 for non-inferiority hypothesis).",0,0,0,0,0
Treatment-emergent adverse events were reported in 130 (88%) of 148 participants in the cefiderocol group and 129 (86%) of 150 in the meropenem group.,0,0,0,0,0
The most common treatment-emergent adverse event was urinary tract infection in the cefiderocol group (23 patients [16%] of 148) and hypokalaemia in the meropenem group (23 patients [15%] of 150).,0,0,0,0,0
Two participants (1%) of 148 in the cefiderocol group and two (1%) of 150 in the meropenem group discontinued the study because of drug-related adverse events.,0,0,1,0,0
The effects of 6 mo of supplementation with probiotics and synbiotics on gut microbiota in the adults with prediabetes: A double blind randomized clinical trial,1,1,0,0,0
Objectives: The evidence of 16S rRNA genes in the gut microbiota distinguished a higher Firmicutes-to-Bacteroidetes ratio in individuals who were obese and had diabetes than in a healthy cohort.,0,0,0,0,0
"So, it seems that the modulation of intestinal microbial ecology by pro-/pre-/synbiotics may contribute to the progression and prevention of metabolic diseases.",0,0,0,0,0
he aim of this study was to assess the effects of probiotics and synbiotic supplementation on the modification of the intestinal microbiome in adults with prediabetes.,0,0,0,0,0
"Methods: In a randomized, double-blinded, placebo-controlled clinical trial, 120 patients with prediabetes were randomly assigned to consume 6 g/d of either a placebo containing maltodextrin (control) or multispecies probiotic or inulin-based synbiotic for 6 mo. ",1,1,0,0,0
 Fecal samples were obtained at baseline and after 6 mo of supplementation.,0,0,0,0,0
"Total energy, macronutrients, and dietary fiber were calculated using a dietary program Nutritionist 4. ",0,0,0,0,0
"DNA was extracted from fecal samples and the numbers of Clostridium perfringens (the represent of phylum Firmicutes), Bacteroides fragilis (the representative of Bacteroidetes) and Escherichia coli (as universal bacteria) were determined by quantitative real-time polymerase chain reactions (qPCR).",0,0,0,0,0
The changes in the relative abundance of the two fecal bacteria before and after supplementation were analyzed and compared within and between groups.,0,0,0,0,0
Results: There were no significant changes in dietary intake during the study. ,0,0,0,0,0
"Six mo of supplementation with probiotics resulted in a statistically significant increase in the abundance of the B. fragilis-to-E.coli ratio (mean difference [MD] ± SE 0.47 ± 0.37, P = 0.04) and decrease of the relative proportion of Firmicutes-to-Bacteroidetes representatives (MD ± SE -118.8 ± 114.6, P = 0.02).",0,0,0,0,0
Synbiotic had no significant effect on the changes in the bacteria.,0,0,0,0,0
 There were no significant differences between the three groups.,0,0,0,0,0
Conclusion: The results of this study suggest that manipulation of the human gut microbiome by using probiotics could provide a potential therapeutic approach in the prevention and management of obesity and metabolic disorders such as diabetes.,0,0,0,0,0
Daily emollient during infancy for prevention of eczema: the BEEP randomised controlled trial,1,0,0,0,0
Background: Skin barrier dysfunction precedes eczema development.,0,0,0,0,0
We tested whether daily use of emollient in the first year could prevent eczema in high-risk children.,0,0,0,0,0
"Methods: We did a multicentre, pragmatic, parallel-group, randomised controlled trial in 12 hospitals and four primary care sites across the UK.",1,0,0,0,0
" Families were approached via antenatal or postnatal services for recruitment of term infants (at least 37 weeks' gestation) at high risk of developing eczema (ie, at least one first-degree relative with parent-reported eczema, allergic rhinitis, or asthma, diagnosed by a doctor).",0,0,0,0,0
Term newborns with a family history of atopic disease were randomly assigned (1:1) to application of emollient daily (either Diprobase cream or DoubleBase gel) for the first year plus standard skin-care advice (emollient group) or standard skin-care advice only (control group).,1,0,0,1,0
The randomisation schedule was created using computer-generated code (stratified by recruiting centre and number of first-degree relatives with atopic disease) and participants were assigned to groups using an internet-based randomisation system.,1,0,0,1,0
"The primary outcome was eczema at age 2 years (defined by UK working party criteria) with analysis as randomised regardless of adherence to allocation for participants with outcome data collected, and adjusting for stratification variables.",1,0,0,0,0
"Findings: 1394 newborns were randomly assigned to study groups between Nov 19, 2014, and Nov 18, 2016; 693 were assigned to the emollient group and 701 to the control group. ",1,0,0,0,0
"Adherence in the emollient group was 88% (466 of 532) at 3 months, 82% (427 of 519) at 6 months, and 74% (375 of 506) at 12 months in those with complete questionnaire data.",0,0,0,0,0
"At age 2 years, eczema was present in 139 (23%) of 598 infants with outcome data collected in the emollient group and 150 (25%) of 612 infants in the control group (adjusted relative risk 0·95 [95% CI 0·78 to 1·16], p=0·61; adjusted risk difference -1·2% [-5·9 to 3·6]). ",0,0,0,0,0
Other eczema definitions supported the results of the primary analysis.,0,0,0,0,0
Mean number of skin infections per child in year 1 was 0·23 (SD 0·68) in the emollient group versus 0·15 (0·46) in the control group; adjusted incidence rate ratio 1·55 (95% CI 1·15 to 2·09).,0,0,0,0,0
Interpretation: We found no evidence that daily emollient during the first year of life prevents eczema in high-risk children and some evidence to suggest an increased risk of skin infections. ,0,0,0,0,0
"Our study shows that families with eczema, asthma, or allergic rhinitis should not use daily emollients to try and prevent eczema in their newborn.",0,0,0,0,0
Testing and linkage to HIV care in China: a cluster-randomised trial,1,0,0,0,0
"Background: Multistage, stepwise HIV testing and treatment procedures can result in lost opportunities to provide timely antiretroviral therapy (ART). ",0,0,0,0,0
 Incomplete engagement of patients along the care cascade translates into high preventable mortality. ,0,0,0,0,0
"We aimed to identify whether a structural intervention to streamline testing and linkage to HIV health care would improve testing completeness, ART initiation, and viral suppression and reduce mortality.",0,0,0,0,0
"Methods: We did a cluster-randomised, controlled trial in 12 hospitals in Guangxi, China. ",1,0,0,0,0
All hospitals were required to be level 2A county general hospitals and ART delivery sites.,0,0,0,0,0
"We selected the 12 most similar hospitals in terms of structural characteristics, past patient caseloads, and testing procedures.",0,0,0,0,0
Hospitals were randomly assigned (1:1) to either the One4All intervention or standard of care.,1,0,0,1,0
Hospitals were randomised in a block design and stratified by the historical rate of testing completeness of the individual hospital during the first 6 months of 2013,1,0,0,0,0
"We enrolled patients aged 18 years or older who were identified as HIV-reactive during screening in study hospitals, who sought inpatient or outpatient care in a study hospital, and who resided in the study catchment area. ",0,0,0,0,0
" The One4All strategy incorporated rapid, point-of-care HIV screening and CD4 counts, and in-parallel viral load testing, to promote fast and complete diagnosis and staging and provide immediate ART to eligible patients.",0,0,0,0,0
Participants in control hospitals received standard care services. ,0,0,0,0,0
"All enrolled patients were assessed for the primary outcome, which was testing completeness within 30 days, defined as completion of three required tests and their post-test counselling. ",0,0,0,0,0
Safety assessments were hospital admissions for the first 90 days and deaths up to 12 months after enrolment. ,0,0,0,0,0
"Findings: Between Feb 24 and Nov 25, 2014, we enrolled 478 patients (232 in One4All, 246 in standard of care).",0,0,0,0,0
"In the One4All group, 177 (76%) of 232 achieved testing completeness within 30 days versus 63 (26%) of 246 in the standard-of-care group (odds ratio 19·94, 95% CI 3·86-103·04, p=0·0004).",0,0,0,0,0
"Although no difference was observed between study groups in the number of hospital admissions at 90 days, by 12 months there were 65 deaths (28%) in the in the One4All group compared with 115 (47%) in the standard-of-care group (Cox proportional hazard ratio 0·44, 0·19-1·01, p=0·0531).",0,0,0,0,0
"Interpretation: Our study provides strong evidence for the benefits of a patient-centred approach to streamlined HIV testing and treatment that could help China change the trajectory of its HIV epidemic, and help to achieve the goal of an end to AIDS.",0,0,0,0,0
"PRIMVAC vaccine adjuvanted with Alhydrogel or GLA-SE to prevent placental malaria: a first-in-human, randomised, double-blind, placebo-controlled study",1,1,0,0,0
Background: PRIMVAC is a VAR2CSA-derived placental malaria vaccine candidate aiming to prevent serious clinical outcomes of Plasmodium falciparum infection during pregnancy,0,0,0,0,0
We assessed the safety and immunogenicity of PRIMVAC adjuvanted with Alhydrogel or glucopyranosyl lipid adjuvant in stable emulsion (GLA-SE) in French and Burkinabe women who were not pregnant.,0,0,0,0,0
"Methods: This first-in-human, randomised, double-blind, placebo-controlled, dose escalation trial was done in two staggered phases, a phase 1A trial in 18-35-year-old women who were malaria naive in a hospital in France and a subsequent phase 1B trial in women who were naturally exposed to P falciparum and nulligravid in the clinical site of a research centre in Burkina Faso. ",1,1,0,0,0
"Volunteers were recruited into four sequential cohorts receiving PRIMVAC intramuscularly at day 0, 28, and 56: two cohorts in France receiving 20 μg or 50 μg of PRIMVAC and then two in Burkina Faso receiving 50 μg or 100 μg of PRIMVAC.",0,0,0,0,0
"Randomisation was centralised, using stratification by cohort and blocks of variable size, and syringes were masked by opaque labels.",1,0,0,1,0
The primary endpoint was the proportion of participants with any grade 3 or higher adverse reaction to vaccination up until day 35.,0,0,0,0,0
Safety at later time points as well as humoral and cellular immunogenicity were assessed in secondary endpoints.,0,0,0,0,0
"Findings: Between April 19, 2016, and July 13, 2017, 68 women (18 in France, 50 in Burkina Faso) of 101 assessed for eligibility were included.",0,0,0,0,0
No serious adverse event related to the vaccine occurred.,0,0,0,0,0
"PRIMVAC antibody titres increased with each dose and seroconversion was observed in all women vaccinated with PRIMVAC (n=57). PRIMVAC antibody titres reached a peak (geometric mean 11 843·0, optical density [OD] 1·0, 95% CI 7559·8-18 552·9 with 100 μg dose and GLA-SE) 1 week after the third vaccination (day 63)",0,0,0,0,0
"Compared with Alhydrogel, GLA-SE tended to improve the PRIMVAC antibody response (geometric mean 2163·5, OD 1·0, 95% CI 1315·7-3557·7 with 100 μg dose and Alhydrogel at day 63). ",0,0,0,0,0
" 1 year after the last vaccination, 20 (71%) of 28 women who were vaccinated with PRIMVAC/Alhydrogel and 26 (93%) of 28 women who were vaccinated with PRIMVAC/GLA-SE still had anti-PRIMVAC antibodies, although antibody magnitude was markedly lower (452·4, OD 1·0, 95% CI 321·8-636·1 with 100 μg dose and GLA-SE).",0,0,0,0,0
"These antibodies reacted with native homologous VAR2CSA expressed by NF54-CSA infected erythrocytes (fold change from baseline at day 63 with 100 μg dose and GLA-SE: 10·74, 95% CI 8·36-13·79). ",0,0,0,0,0
"Limited cross-recognition, restricted to sera collected from women that received the 100 μg PRIMVAC dose, was observed against heterologous VAR2CSA variants expressed by FCR3-CSA (fold change from baseline at day 63: 1·49, 95% CI 1·19-1·88) and 7G8-CSA infected erythrocytes (1·2, 1·08-1·34).",0,0,0,0,0
"Among 1650 randomized patients (mean age, 72.1 years [SD, 5.4 years]; 63.6% women; 91.0% white), 1597 (96.8%) received at least 1 dose of warfarin therapy and completed the trial (n = 808 in genotype-guided group vs n = 789 in clinically guided group)",1,0,0,0,0
"Patients were randomized 1:1 using a computerized system that stratified by site, type of arthroplasty (knee or hip), and race (black vs other)",1,0,0,1,0
The goal of this multicenter randomized clinical trial was to determine whether genotype-guided warfarin dosing reduced adverse events.,1,0,0,0,0
"Twenty-three patients in the genotype-guided group and 30 in the clinically guided group were excluded because they did not undergo arthroplasty, withdrew from the trial, never received warfarin, or were discovered to have met an exclusion criterion after randomization",0,0,1,0,0
This randomized controlled trial enrolled adult human subjects after upper- abdominal surgery from January 2017 to November 2018,1,0,0,0,0
"Among the remaining 209 patients who consented, 132 patients were not randomized due to predefined exclusion criteria",0,0,1,0,0
We enrolled 96 patients with SJS-TEN in a randomized trial to compare the effects of the TNF-α antagonist etanercept versus traditional corticosteroids,1,0,0,0,0
"Among these participants, 3 failed the screening (CD4 count <200 cells/mm3) and 2 had changes in their diagnosis (Figure 2 and Supplemental Table 3)",0,0,1,0,0
"This double-blind, randomized, parallel-group study was conducted at 22 university hospitals and research centers in Japan from March 2012 to April 2014 (see Appendix APPENDIX A)",1,1,0,0,0
Patients who participated in the 4-week screening period and met the entry criteria were enrolled and randomized (by computer) to the HCQ group or the placebo group in a 3:1 ratio with a block size of 4,1,0,0,1,0
"Randomization was stratified according to a CLASI activity score of <9 or ≥9 on day 1, which was the median value of the CLASI activity score at baseline in a previous Japanese cohort study 17.",1,0,0,1,0
"This double-blind, randomized, baseline-controlled study demonstrated a significant reduction in the CLASI activity score in both the HCQ-treated group and the placebo-treated group at week 16",1,1,0,0,0
"Two randomized, double-blind, multicenter, parallel-group studies (one flexible-dose, one forced-dose) with placebo reference arms were conducted.",1,1,0,0,0
"At the start of double-blind treatment, participants were randomized (2:2:1) using an interactive web-response system (IWRS) to once-daily lisdexamfetamine, OROS-MPH, or placebo, respectively",1,0,0,1,0
"To maintain blinding, treatments were identical in appearance; participants were also instructed to take one capsule from two separate bottles.",0,0,0,0,1
"Numbers of withdrawals, losses to follow-up, and missing outcome data, and the number and proportion of cases excluded from the analyses by outcome measure and treatment group are shown in the appendix (pp 25–27)",0,0,1,0,0
Distinct effects of losartan and atenolol on vascular stiffness in Marfan syndrome,0,0,0,0,0
"We conducted a randomized, double-blind trial of losartan (100 mg QD) versus atenolol (50 mg QD) for 6 months in adults with Marfan syndrome.",1,1,0,0,0
"Carotid-femoral pulse wave velocity (PWV), central augmentation index (AIx), aortic diameter and left ventricular (LV) function were assessed with arterial tonometry and echocardiography.",0,0,0,0,0
"Thirty-four subjects (18 female; median age 35 years, IQR 27, 45) were randomized.",1,0,0,0,0
A prospective randomization process was performed to assign participants to either aliskiren treatment (150-300mg orally per day) or no aliskiren treatment (negative control) in an open-label design.,1,0,0,0,0
"We undertook a nonrandomized, open-label, feasibility, and safety study using autologous keratinocytes transduced with a lentiviral vector encoding SPINK5 under the control of the human involucrin promoter.",0,0,0,0,0
"Effect of early low-dose hydrocortisone on survival without bronchopulmonary dysplasia in extremely preterm infants (PREMILOC): a double-blind, placebo-controlled, multicentre, randomised trial",1,1,0,0,0
"In this double-blind, placebo-controlled, randomised trial done at 21 French tertiary-care neonatal intensive care units (NICUs), we randomly assigned (1:1), via a secure study website, extremely preterm infants inborn (born in a maternity ward at the same site as the NICU) at less than 28 weeks of gestation to receive either intravenous low-dose hydrocortisone or placebo during the first 10 postnatal days. ",1,1,0,1,0
"Infants randomly assigned to the hydrocortisone group received 1 mg/kg of hydrocortisone hemisuccinate per day divided into two doses per day for 7 days, followed by one dose of 0·5 mg/kg per day for 3 days.",1,0,0,0,0
Randomisation was stratified by gestational age and all infants were enrolled by 24 h after birth.,1,0,0,0,0
"Study investigators, parents, and patients were masked to treatment allocation.",0,0,0,0,1
"1072 neonates were screened between May 25, 2008, and Jan 31, 2014, of which 523 were randomly assigned (256 hydrocortisone, 267 placebo). ",1,0,0,0,0
255 infants on hydrocortisone and 266 on placebo were included in analyses after parents withdrew consent for one child in each group.,0,0,1,0,0
"Randomization was performed preoperatively using sequentially numbered, opaque, sealed envelopes, and patients were informed of the results of randomization.",1,0,0,1,0
Randomisation was done by use of three-digit randomisation codes in envelopes provided by a data management service.,1,0,0,1,0
"The participants and investigators were masked to treatment assignment, which was maintained by use of sterile saline as a placebo injection. ",0,0,0,0,1
"Healthy men and women aged 18-45 years with no comorbidities were randomly assigned, by computer-generated block randomisation (block size of 14), to receive either one of three escalating doses of the measles-virus-based candidate vaccine (low dose [1·5 × 10(4) median tissue culture infection doses (TCID50) per 0·05 mL], medium dose [7·5 × 10(4) TCID50 per 0·25 mL], or high dose [3·0 × 10(5) TCID50 per 1·0 mL]), or the active comparator-Priorix. ",1,0,0,1,0
Participants and study investigators were masked to group allocation.,0,0,0,0,1
"We analyzed hospital and immunization records of 104 patients with CHH and measured serum antibodies to measles, mumps, rubella, and varicella zoster virus (VZV) in all patients who agreed to blood sampling (n = 50). ",0,0,1,0,0
Three patients in the sertraline group and three patients in the placebo group were lost to follow-up and therefore discontinued before study end.,0,0,1,0,0
"In this double-blind, randomised, placebo-controlled trial, we recruited HIV-positive adults with cryptococcal meningitis from two hospitals in Uganda. ",1,1,0,0,0
Participants were randomly assigned (1:1) to receive standard therapy with 7-14 days of intravenous amphotericin B (0·7-1·0 mg/kg per day) and oral fluconazole (starting at 800 mg/day) with either adjunctive sertraline or placebo.,1,0,0,1,0
"Fifteen patients left the study within the first six months: voluntarily n = 12, because of neutropenia n = 1, and death n = 1. ",0,0,1,0,0
Twelve patients left the study within the second six months: voluntarily n = 11 and death n = 1.,0,0,1,0,0
A pilot randomized controlled trial of complete bed rest versus activity restriction after preterm premature rupture of the membranes,1,0,0,0,0
"We did a double-blind, multicentre, randomised placebo-controlled trial at 33 hospital maternity units in England and Wales. ",1,1,0,1,0
"The primary outcome analysis included 304 women and 322 infants in the ursodeoxycholic acid group, and 300 women and 318 infants in the placebo group (consent to use data was withdrawn for 1 woman and 2 infants). ",0,0,1,0,0
"Participants were randomly assigned 1:1 to ursodeoxycholic acid or placebo, given as two oral tablets a day at an equivalent dose of 500 mg twice a day.",1,0,0,1,0
"Data after randomization were not available for 10 women in the metformin group and 8 in the insulin group, who therefore could not be included in the analysis. ",1,0,1,0,0
We randomly assigned 751 women with gestational diabetes mellitus at 20 to 33 weeks of gestation to open treatment with metformin (with supplemental insulin if required) or insulin.,1,0,0,0,0
"After refusals (20%) and attrition (25%), the final sample comprised 84 depressed pregnant women.",0,0,1,0,0
"We separately consented and enrolled 86 children and, of these, were able to obtain buffy coat speciments on 83/86 (97%).",0,0,1,0,0
"One child subsequently withdrew consent just for HLA typing, for a final of 82 children on whom we performed HLA typing.",0,0,1,0,0
Six patients from group A and eight patients from group B were either lost to follow-up or found the procedure painful and withdrew from the study (Figure 1).,0,0,1,0,0
 Patients were randomly assigned into two groups.,1,0,0,0,0
"This prospective, comparative, single-blinded study was initiated after approval by the institutional ethics committee.",0,0,0,0,0
A total of 71 participants (VAR-PE: 31; VAR:40) were identified as seropositive at baseline (VZV antibody ≥1.25 gpELISA units/mL) and excluded from the PP analysis.,0,0,1,0,0
"The PP population excluded participants who had important protocol deviations with the potential to impact the immunogenicity analyses (not compliant with immunogenicity specimen collection, n = 8; receipt of systemic steroids 7 days prior to vaccination or during the 42-day safety follow-up period, n = 6; receipt of improperly stored study treatment, n = 2; improper reconstitution of vaccine, n = 1), as well as participants who did not receive any study vaccine, n = 1, did not have postvaccination immunogenicity assessments, n = 45, or had seropositive status at baseline, n = 77.",0,0,1,0,0
"A double-blind, randomized, multicenter, controlled study to evaluate the immunogenicity, safety, and tolerability of varicella vaccine (VARIVAX™) passage extension 34 (PE34) process administered concomitantly with measles, mumps, and rubella vaccine (M-M-R™ II)",1,1,0,0,0
"Subjects were assigned randomized treatment in a 1:1 ratio to VAR-PE or VAR, without stratiﬁcation.",1,0,0,1,0
"Protection against varicella with two doses of combined measles-mumps-rubella-varicella vaccine or one dose of monovalent varicella vaccine: 10-year follow-up of a phase 3 multicentre, observer-blind, randomised, controlled trial",1,0,0,0,0
"This was a phase 3b follow-up of an observer-blinded, randomised, controlled trial. In phase a, children aged 12-22 months (at first vaccination) from Czech Republic (Czechia), Greece, Italy, Lithuania, Norway, Poland, Romania, Russia, Slovakia, and Sweden were randomly assigned by computer-generated randomisation list (3:3:1) to receive two doses of MMRV, one dose of MMR and one dose of varicella vaccine, or two doses of MMR, 42 days apart.",1,0,0,1,0
"This was a phase III, randomised, double-blind, non-inferiority study of the MMR-Bio administered in infants immunised at health care units in Pará, Brazil, from February 2015 to January 2016.",1,1,0,0,0
"After signing the informed consent, 79 of the 1,639 participants were excluded before receiving the MMR vaccine, mainly because of withdrawals and “other reasons”.",0,0,1,0,0
"Randomisation was conducted by blocks of size 4, with 390 infants in each arm; about 1,170 infants comprised the MMR-Bio group and 390 comprised the MMR-GSK group (3:1 allocation ratio).",1,0,0,1,0
"The randomisation list was drawn up by the BioForm system (electronic system used to record patients’ clinical information) with numbers from 1 to 1,560, which was not disclosed to the field work team in order to keep the blindness of the participants and the study team.",1,0,0,1,1
"Two children were contraindicated for the MMR vaccine at 9 months of age and were excluded from the analysis: one was diagnosed with Kawasaki disease at 8.5 months and received intravenous Ig and the other naturally contracted measles at the age of 9 months, a few days before the scheduled MMR vaccine visit",0,0,1,0,0
"There were 11 discontinuations during the study period, with adverse events the most common reason for discontinuation (n = 6) (see Supplementary Figure S1).",0,0,1,0,0
"CARIMA (Evaluation of Cardiovascular Risk Markers in Psoriasis Patients Treated with Secukinumab) was a 52-week, randomized, double-blind, placebo-controlled, exploratory trial in patients with moderate to severe plaque psoriasis without clinical CV disease.",1,1,0,0,0
Patients were assigned to one of the two trial arms (probiotics or control) following a computerized randomization list previously prepared by a blinded statistician for the treatment administered and for the results during all data analysis.,1,1,0,1,1
"Randomization was performed according to the baseline variables: sex, age and age of onset of psoriasis.",1,0,0,1,0
Patients 18 years or older with inadequately controlled psoriasis for more than 6 months were randomized 2:1 to receive secukinumab or placebo (see Fig E1 in this article's Online Repository at www.jacionline.org). ,1,0,0,1,0
"Thirty-six treatment-naïve patients will be randomized in a 1:1:1 ratio to Arm A1b, A2 or B1b, whereas another 136 treatment-naïve patients will be randomized in 1:1 ratio to Arm A1a or B1a.",1,0,0,1,0
"Of these, 16 did not receive VSTs, either because intervention was considered not required (n = 4) or because the patients were ineligible (n = 12; Appendix Table A4, online only)",0,0,1,0,0
Seven were excluded subsequently; one from ineligibility (born <36 weeks) and six for failing to provide any swabs.,0,0,1,0,0
Three subjects were excluded due to incomplete nasal cytokine data.,0,0,1,0,0
"A total of 271 participants (90% in the prazosin group and 89% in the placebo group) completed the 10-week primary outcome assessments, and 284 (94% in the prazosin group and 93% in the placebo group) completed one or more of the 10-week primary outcome assessments; 59 participants (20% in the prazosin group and 19% in the placebo group) withdrew from the trial before the 26-week visit.",0,0,1,0,0
"Using a web-based randomisation system, we randomly assigned participants (1:1:2) to three different dose groups of MDMA plus psychotherapy: 30 mg (active control), 75 mg, or 125 mg.",1,0,0,1,0
"We masked investigators, independent outcome raters, and participants until after the primary endpoint.",0,0,0,0,1
"We did a randomised, double-blind, dose-response, phase 2 trial at an outpatient psychiatric clinic in the USA. ",1,1,0,0,0
"Among 38 participants who were enrolled in the study, 9 participants did not start the THR program due to several reasons (personal matters, n = 5; injuries, n = 2; logistic issues, n = 2).",0,0,1,0,0
"Nineteen veterans were excluded (13 did not meet inclusion criteria, and 6 for a variety of other reasons).",0,0,1,0,0
"We used a randomized wait-list controlled design with repeated measures of U.S. military veterans to address our specific aim to test the efficacy of a 6-week therapeutic horseback riding (THR) program for decreasing PTSD symptoms and increasing coping self-efficacy, emotion regulation, social and emotional loneliness.",1,0,0,0,0
Fifty-seven participants were recruited and 29 enrolled in the randomized trial.,1,0,0,0,0
They were randomly assigned to either the horse riding group (n = 15) or a wait-list control group (n = 14).,1,0,0,0,0
"Of the 68 Veterans who were self- or provider-referred to the program, 25 (36.7%) were ineligible due to (i) absence of a PTSD diagnosis (n = 3); participation in ongoing intense psychotherapy (n = 4) or inpatient substance abuse program (n = 2); current resident of the Domiciliary (n = 8) and inability to participate due to distance of residence from the VA (n = 8).",0,0,1,0,0
Only 3 (4.4%) Veterans declined participation due to lack of interest.,0,0,1,0,0
"The study was designed as a prospective, delayed-entry randomized pilot trial.",1,0,0,0,0
Music-instruction intervention for treatment of post-traumatic stress disorder: a randomized pilot study,1,0,0,0,0
"The Consort diagram (Figure ​(Figure1)1) shows 1,164 eligible patients, 309 died in ICU or shortly after discharge, 65 refused to take part and 433 were excluded because of previous psychotic illness (n = 6), attempted suicide (n = 3), age younger than 16 years (n = 2), distance too great for follow-up (n = 10), transferred to another ICU (n = 274) or unresolving confusion at one to two weeks post-ICU admission (n = 138).",0,0,1,0,0
Data analysis was performed blind using coded data and the code only broken once the analysis was complete.,0,1,0,0,1
Intensive care patients with an ICU stay of more than 72 hours were recruited to a randomised controlled trial examining the effect of a diary outlining the details of the patients ICU stay on the development of acute PTSD. ,1,0,0,0,0
One patient dropped out after two sessions as she was called to a family emergency abroad.,0,0,1,0,0
"A subsequent randomized controlled trial compared CT () and a 3-month waitlist condition (WL, ).",1,0,0,0,0
"Eligible patients were randomly allocated to one of four groups: group A, simulated TEAS combined with sertraline; group B, simulated TEAS combined with CBT; group C, active TEAS combined with CBT; and group D, active TEAS combined with sertraline plus CBT, in a ratio of 1:1:1:1. ",1,0,0,1,0
"To ensure allocation concealment, the group allocation was done in a partially double-blind manner.",0,1,0,0,0
"Clinical assessors, data collectors, and analysts were blinded to patient treatment.",0,0,0,0,1
One patient with PTSD dropped out of the study as they refused a follow-up session due to distress associated with the scanning procedure.,0,0,1,0,0
" Two participants (one PTSD and one TEC) were excluded from all imaging analyses: one had a major frontal artefact and with the other participant, there were technical issues with the scanner.",0,0,1,0,0
"Participants exposed to earthquakes with (n = 11) and without post-traumatic stress disorder (n = 11) underwent two functional magnetic resonance imaging scans, 1-week apart, in a double-blind, placebo-controlled, counter-balanced design. ",0,1,0,0,0
"In other words, the assessors and data analyzer were blinded to the group allocation.",0,0,0,1,0
 A participant in the intervention group and two participants in the control group were excluded from the study because their babies were admitted to the intensive care unit (Fig. 1). ,0,0,1,0,0
"Effectiveness of midwife-led brief counseling intervention on post-traumatic stress disorder, depression, and anxiety symptoms of women experiencing a traumatic childbirth: a randomized controlled trial",1,0,0,0,0
They were randomly assigned into two groups: the intervention (n = 45) or control groups (n = 45) via block randomization method using 4-way blocks. ,1,0,0,1,0
The randomization code was generated by a web-based randomization system.,0,0,0,1,0
The study was double-blinded.,0,1,0,0,0